{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T04:58:25Z","timestamp":1794373105391,"version":"4.9.0"},"reference-count":443,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Immunol"],"DOI":"10.1038\/s41577-026-01322-1","type":"journal-article","created":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T12:05:56Z","timestamp":1782993956000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["A guide to CAR T cell therapies: development, current status and future prospects"],"prefix":"10.1038","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5724-4183","authenticated-orcid":false,"given":"Hind","family":"Rafei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1326-5898","authenticated-orcid":false,"given":"Ranjan","family":"Upadhyay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4658-055X","authenticated-orcid":false,"given":"Padmanee","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,2]]},"reference":[{"key":"1322_CR1","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1038\/s41577-025-01229-3","volume":"26","author":"ZL Lamplugh","year":"2026","unstructured":"Lamplugh, Z. L., Wellhausen, N., June, C. H. & Fan, Y. Microenvironmental regulation of solid tumour resistance to CAR T cell therapy. Nat. Rev. Immunol. 26, 230\u2013248 (2026).","journal-title":"Nat. Rev. Immunol."},{"key":"1322_CR2","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1038\/s41577-025-01174-1","volume":"25","author":"Y-R Li","year":"2025","unstructured":"Li, Y.-R., Zhu, Y., Halladay, T. & Yang, L. In vivo CAR engineering for immunotherapy. Nat. Rev. Immunol. 25, 725\u2013744 (2025).","journal-title":"Nat. Rev. Immunol."},{"key":"1322_CR3","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1038\/s41577-024-01035-3","volume":"24","author":"JB Chung","year":"2024","unstructured":"Chung, J. B., Brudno, J. N., Borie, D. & Kochenderfer, J. N. Chimeric antigen receptor T cell therapy for autoimmune disease. Nat. Rev. Immunol. 24, 830\u2013845 (2024).","journal-title":"Nat. Rev. Immunol."},{"key":"1322_CR4","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1038\/s41577-024-01093-7","volume":"25","author":"S Minguet","year":"2025","unstructured":"Minguet, S., Maus, M. V. & Schamel, W. W. From TCR fundamental research to innovative chimeric antigen receptor design. Nat. Rev. Immunol. 25, 212\u2013224 (2025).","journal-title":"Nat. Rev. Immunol."},{"key":"1322_CR5","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1126\/science.3278377","volume":"239","author":"AM Weissman","year":"1988","unstructured":"Weissman, A. M. et al. Molecular cloning of the \u03b6 chain of the T cell antigen receptor. Science 239, 1018\u20131021 (1988).","journal-title":"Science"},{"key":"1322_CR6","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1038\/320232a0","volume":"320","author":"Z Dembi\u0107","year":"1986","unstructured":"Dembi\u0107, Z. et al. Transfer of specificity by murine \u03b1 and \u03b2 T-cell receptor genes. Nature 320, 232\u2013238 (1986).","journal-title":"Nature"},{"key":"1322_CR7","doi-asserted-by":"publisher","first-page":"5387","DOI":"10.1073\/pnas.080078297","volume":"97","author":"PD Holler","year":"2000","unstructured":"Holler, P. D. et al. In vitro evolution of a T cell receptor with high affinity for peptide\/MHC. Proc. Natl Acad. Sci. USA 97, 5387\u20135392 (2000).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1322_CR8","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1016\/0092-8674(91)90314-O","volume":"64","author":"BA Irving","year":"1991","unstructured":"Irving, B. A. & Weiss, A. The cytoplasmic domain of the T cell receptor \u03b6 chain is sufficient to couple to receptor-associated signal transduction pathways. Cell 64, 891\u2013901 (1991). This foundational study shows that the CD3\u03b6 chain alone is sufficient to trigger T cell activation, paving the way for the design of first-generation CARs.","journal-title":"Cell"},{"key":"1322_CR9","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1016\/0092-8674(91)90327-U","volume":"64","author":"C Romeo","year":"1991","unstructured":"Romeo, C. & Seed, B. Cellular immunity to HIV activated by CD4 fused to T cell or Fc receptor polypeptides. Cell 64, 1037\u20131046 (1991).","journal-title":"Cell"},{"key":"1322_CR10","doi-asserted-by":"publisher","first-page":"8905","DOI":"10.1073\/pnas.88.20.8905","volume":"88","author":"F Letourneur","year":"1991","unstructured":"Letourneur, F. & Klausner, R. D. T-cell and basophil activation through the cytoplasmic tail of T-cell-receptor \u03b6 family proteins. Proc. Natl Acad. Sci. USA 88, 8905\u20138909 (1991).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1322_CR11","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1016\/0006-291X(87)90502-X","volume":"149","author":"Y Kuwana","year":"1987","unstructured":"Kuwana, Y. et al. Expression of chimeric receptor composed of immunoglobulin-derived V regions and T-cell receptor-derived C regions. Biochem. Biophys. Res. Commun. 149, 960\u2013968 (1987). This study is the earliest report of a chimeric receptor fusing antibody variable regions to TCR constant domains, establishing the structural proof-of-concept for CAR design.","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"1322_CR12","doi-asserted-by":"publisher","first-page":"10024","DOI":"10.1073\/pnas.86.24.10024","volume":"86","author":"G Gross","year":"1989","unstructured":"Gross, G., Waks, T. & Eshhar, Z. Expression of immunoglobulin\u2013T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc. Natl Acad. Sci. USA 86, 10024\u201310028 (1989). This seminal paper describes the \u2018T-body\u2019 or CAR, establishing the concept of redirecting T cell specificity using antibody-derived domains to recognize antigens in an MHC-independent manner.","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1322_CR13","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1073\/pnas.90.2.720","volume":"90","author":"Z Eshhar","year":"1993","unstructured":"Eshhar, Z., Waks, T., Gross, G. & Schindler, D. G. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the \u03b3 or \u03b6 subunits of the immunoglobulin and T-cell receptors. Proc. Natl Acad. Sci. USA 90, 720\u2013724 (1993). This study introduces the single-chain chimeric receptor design (scFv fused to signalling domains), which became the standard structural prototype for first-generation CARs and is the backbone of modern CAR T cell therapies.","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1322_CR14","doi-asserted-by":"publisher","first-page":"4318","DOI":"10.1073\/pnas.91.10.4318","volume":"91","author":"D Moritz","year":"1994","unstructured":"Moritz, D., Wels, W., Mattern, J. & Groner, B. Cytotoxic T lymphocytes with a grafted recognition specificity for ERBB2-expressing tumor cells. Proc. Natl Acad. Sci. USA 91, 4318\u20134322 (1994).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1322_CR15","doi-asserted-by":"publisher","first-page":"6577","DOI":"10.4049\/jimmunol.151.11.6577","volume":"151","author":"I Stancovski","year":"1993","unstructured":"Stancovski, I. et al. Targeting of T lymphocytes to Neu\/HER2-expressing cells using chimeric single chain Fv receptors. J. Immunol. 151, 6577\u20136582 (1993).","journal-title":"J. Immunol."},{"key":"1322_CR16","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1084\/jem.178.1.361","volume":"178","author":"P Hwu","year":"1993","unstructured":"Hwu, P. et al. Lysis of ovarian cancer cells by human lymphocytes redirected with a chimeric gene composed of an antibody variable region and the Fc receptor \u03b3 chain. J. Exp. Med. 178, 361\u2013366 (1993).","journal-title":"J. Exp. Med."},{"key":"1322_CR17","first-page":"3369","volume":"55","author":"P Hwu","year":"1995","unstructured":"Hwu, P. et al. In vivo antitumor activity of T cells redirected with chimeric antibody\/T-cell receptor genes. Cancer Res. 55, 3369\u20133373 (1995).","journal-title":"Cancer Res."},{"key":"1322_CR18","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1002\/eji.1830230705","volume":"23","author":"T Brocker","year":"1993","unstructured":"Brocker, T., Peter, A., Traunecker, A. & Karjalainen, K. New simplified molecular design for functional T cell receptor. Eur. J. Immunol. 23, 1435\u20131439 (1993).","journal-title":"Eur. J. Immunol."},{"key":"1322_CR19","first-page":"1116","volume":"58","author":"A Hombach","year":"1998","unstructured":"Hombach, A. et al. An anti-CD30 chimeric receptor that mediates CD3-\u03b6-independent T-cell activation against Hodgkin\u2019s lymphoma cells in the presence of soluble CD30. Cancer Res. 58, 1116\u20131119 (1998).","journal-title":"Cancer Res."},{"key":"1322_CR20","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1053\/bbmt.1998.v4.pm9763110","volume":"4","author":"M Jensen","year":"1998","unstructured":"Jensen, M., Tan, G., Forman, S., Wu, A. M. & Raubitschek, A. CD20 is a molecular target for scFvFc:\u03b6 receptor redirected T cells: implications for cellular immunotherapy of CD20+ malignancy. Biol. Blood Marrow Transpl. 4, 75\u201383 (1998).","journal-title":"Biol. Blood Marrow Transpl."},{"key":"1322_CR21","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1053\/gast.1997.v113.pm9322511","volume":"113","author":"A Hombach","year":"1997","unstructured":"Hombach, A. et al. T cell targeting of TAG72+ tumor cells by a chimeric receptor with antibody-like specificity for a carbohydrate epitope. Gastroenterology 113, 1163\u20131170 (1997).","journal-title":"Gastroenterology"},{"key":"1322_CR22","doi-asserted-by":"publisher","first-page":"182","DOI":"10.4049\/jimmunol.166.1.182","volume":"166","author":"NM Haynes","year":"2001","unstructured":"Haynes, N. M. et al. Redirecting mouse CTL against colon carcinoma: superior signaling efficacy of single-chain variable domain chimeras containing TCR-\u03b6 vs Fc\u03b5RI-\u03b3. J. Immunol. 166, 182\u2013187 (2001).","journal-title":"J. Immunol."},{"key":"1322_CR23","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1038\/sj.neo.7900018","volume":"1","author":"MC Gong","year":"1999","unstructured":"Gong, M. C. et al. Cancer patient T cells genetically targeted to prostate-specific membrane antigen specifically lyse prostate cancer cells and release cytokines in response to prostate-specific membrane antigen. Neoplasia 1, 123\u2013127 (1999).","journal-title":"Neoplasia"},{"key":"1322_CR24","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1084\/jem.181.5.1653","volume":"181","author":"T Brocker","year":"1995","unstructured":"Brocker, T. & Karjalainen, K. Signals through T cell receptor-\u03b6 chain alone are insufficient to prime resting T lymphocytes. J. Exp. Med. 181, 1653\u20131659 (1995).","journal-title":"J. Exp. Med."},{"key":"1322_CR25","first-page":"3392","volume":"14","author":"PH Stein","year":"1994","unstructured":"Stein, P. H., Fraser, J. D. & Weiss, A. The cytoplasmic domain of CD28 is both necessary and sufficient for costimulation of interleukin-2 secretion and association with phosphatidylinositol 3\u2032-kinase. Mol. Cell. Biol. 14, 3392\u20133402 (1994).","journal-title":"Mol. Cell. Biol."},{"key":"1322_CR26","doi-asserted-by":"publisher","first-page":"2304","DOI":"10.1002\/eji.1830261006","volume":"26","author":"L Alvarez-Vallina","year":"1996","unstructured":"Alvarez-Vallina, L. & Hawkins, R. E. Antigen-specific targeting of CD28-mediated T cell co-stimulation using chimeric single-chain antibody variable fragment\u2013CD28 receptors. Eur. J. Immunol. 26, 2304\u20132309 (1996).","journal-title":"Eur. J. Immunol."},{"key":"1322_CR27","doi-asserted-by":"publisher","first-page":"3155","DOI":"10.1182\/blood-2002-04-1041","volume":"100","author":"NM Haynes","year":"2002","unstructured":"Haynes, N. M. et al. Single-chain antigen recognition receptors that costimulate potent rejection of established experimental tumors. Blood 100, 3155\u20133163 (2002).","journal-title":"Blood"},{"key":"1322_CR28","doi-asserted-by":"publisher","first-page":"2791","DOI":"10.4049\/jimmunol.161.6.2791","volume":"161","author":"HM Finney","year":"1998","unstructured":"Finney, H. M., Lawson, A. D., Bebbington, C. R. & Weir, A. N. Chimeric receptors providing both primary and costimulatory signaling in T cells from a single gene product. J. Immunol. 161, 2791\u20132797 (1998). This study provides the first molecular description of a \u2018second-generation\u2019 CAR, demonstrating that fusing the CD28 co-stimulatory domain with the CD3\u03b6 chain enables dual signalling from a single receptor.","journal-title":"J. Immunol."},{"key":"1322_CR29","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1038\/nbt0102-70","volume":"20","author":"J Maher","year":"2002","unstructured":"Maher, J., Brentjens, R. J., Gunset, G., Rivi\u00e8re, I. & Sadelain, M. Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCR\u03b6\/CD28 receptor. Nat. Biotechnol. 20, 70\u201375 (2002).","journal-title":"Nat. Biotechnol."},{"key":"1322_CR30","doi-asserted-by":"publisher","first-page":"6123","DOI":"10.4049\/jimmunol.167.11.6123","volume":"167","author":"A Hombach","year":"2001","unstructured":"Hombach, A. et al. Tumor-specific T cell activation by recombinant immunoreceptors: CD3\u03b6 signaling and CD28 costimulation are simultaneously required for efficient IL-2 secretion and can be integrated into one combined CD28\/CD3\u03b6 signaling receptor molecule. J. Immunol. 167, 6123\u20136131 (2001).","journal-title":"J. Immunol."},{"key":"1322_CR31","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1097\/CJI.0b013e318194a6e8","volume":"32","author":"D Hollyman","year":"2009","unstructured":"Hollyman, D. et al. Manufacturing validation of biologically functional T cells targeted to CD19 antigen for autologous adoptive cell therapy. J. Immunother. 32, 169\u2013180 (2009).","journal-title":"J. Immunother."},{"key":"1322_CR32","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.1172\/JCI46110","volume":"121","author":"B Savoldo","year":"2011","unstructured":"Savoldo, B. et al. CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J. Clin. Invest. 121, 1822\u20131826 (2011).","journal-title":"J. Clin. Invest."},{"key":"1322_CR33","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1084\/jem.188.4.619","volume":"188","author":"A Krause","year":"1998","unstructured":"Krause, A. et al. Antigen-dependent CD28 signaling selectively enhances survival and proliferation in genetically modified activated human primary T lymphocytes. J. Exp. Med. 188, 619\u2013626 (1998).","journal-title":"J. Exp. Med."},{"key":"1322_CR34","doi-asserted-by":"publisher","first-page":"104","DOI":"10.4049\/jimmunol.172.1.104","volume":"172","author":"HM Finney","year":"2004","unstructured":"Finney, H. M., Akbar, A. N. & Lawson, A. D. G. Activation of resting human primary T cells with chimeric receptors: costimulation from CD28, inducible costimulator, CD134, and CD137 in series with signals from the TCR\u03b6 chain. J. Immunol. 172, 104\u2013113 (2004).","journal-title":"J. Immunol."},{"key":"1322_CR35","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/sj.leu.2403302","volume":"18","author":"C Imai","year":"2004","unstructured":"Imai, C. et al. Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia. Leukemia 18, 676\u2013684 (2004).","journal-title":"Leukemia"},{"key":"1322_CR36","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1038\/mt.2009.83","volume":"17","author":"MC Milone","year":"2009","unstructured":"Milone, M. C. et al. Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Mol. Ther. J. Am. Soc. Gene Ther. 17, 1453\u20131464 (2009). This work validates 4-1BB (CD137) as a superior co-stimulatory domain for enhancing T cell persistence, forming the basis for the clinical success of tisa-cel.","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"1322_CR37","doi-asserted-by":"publisher","DOI":"10.1002\/cti2.1049","volume":"8","author":"R Weinkove","year":"2019","unstructured":"Weinkove, R., George, P., Dasyam, N. & McLellan, A. D. Selecting costimulatory domains for chimeric antigen receptors: functional and clinical considerations. Clin. Transl. Immunol. 8, e1049 (2019).","journal-title":"Clin. Transl. Immunol."},{"key":"1322_CR38","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.immuni.2016.01.021","volume":"44","author":"OU Kawalekar","year":"2016","unstructured":"Kawalekar, O. U. et al. Distinct signaling of coreceptors regulates specific metabolism pathways and impacts memory development in CAR T cells. Immunity 44, 380\u2013390 (2016).","journal-title":"Immunity"},{"key":"1322_CR39","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.ccell.2015.09.004","volume":"28","author":"Z Zhao","year":"2015","unstructured":"Zhao, Z. et al. Structural design of engineered costimulation determines tumor rejection kinetics and persistence of CAR T cells. Cancer Cell 28, 415\u2013428 (2015).","journal-title":"Cancer Cell"},{"key":"1322_CR40","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1038\/nrd4597","volume":"14","author":"SJC van der Stegen","year":"2015","unstructured":"van der Stegen, S. J. C., Hamieh, M. & Sadelain, M. The pharmacology of second-generation chimeric antigen receptors. Nat. Rev. Drug Discov. 14, 499\u2013509 (2015).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1322_CR41","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/nm.3838","volume":"21","author":"AH Long","year":"2015","unstructured":"Long, A. H. et al. 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. Nat. Med. 21, 581\u2013590 (2015).","journal-title":"Nat. Med."},{"key":"1322_CR42","doi-asserted-by":"publisher","first-page":"3360","DOI":"10.1073\/pnas.0813101106","volume":"106","author":"C Carpenito","year":"2009","unstructured":"Carpenito, C. et al. Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. Proc. Natl Acad. Sci. USA 106, 3360\u20133365 (2009).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1322_CR43","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1038\/nm1676","volume":"13","author":"MT Stephan","year":"2007","unstructured":"Stephan, M. T. et al. T cell-encoded CD80 and 4-1BBL induce auto- and transcostimulation, resulting in potent tumor rejection. Nat. Med. 13, 1440\u20131449 (2007).","journal-title":"Nat. Med."},{"key":"1322_CR44","doi-asserted-by":"publisher","first-page":"2935","DOI":"10.1002\/ijc.25960","volume":"129","author":"AA Hombach","year":"2011","unstructured":"Hombach, A. A. & Abken, H. Costimulation by chimeric antigen receptors revisited the T cell antitumor response benefits from combined CD28\u2013OX40 signalling. Int. J. Cancer 129, 2935\u20132944 (2011).","journal-title":"Int. J. Cancer"},{"key":"1322_CR45","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.96976","volume":"3","author":"S Guedan","year":"2018","unstructured":"Guedan, S. et al. Enhancing CAR T cell persistence through ICOS and 4-1BB costimulation. JCI Insight 3, e96976 (2018).","journal-title":"JCI Insight"},{"key":"1322_CR46","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1038\/s41375-019-0417-9","volume":"33","author":"MR Collinson-Pautz","year":"2019","unstructured":"Collinson-Pautz, M. R. et al. Constitutively active MyD88\/CD40 costimulation enhances expansion and efficacy of chimeric antigen receptor T cells targeting hematological malignancies. Leukemia 33, 2195\u20132207 (2019).","journal-title":"Leukemia"},{"key":"1322_CR47","doi-asserted-by":"publisher","first-page":"3146","DOI":"10.1016\/j.ymthe.2023.09.021","volume":"31","author":"L Tang","year":"2023","unstructured":"Tang, L., Pan, S., Wei, X., Xu, X. & Wei, Q. Arming CAR-T cells with cytokines and more: Innovations in the fourth-generation CAR-T development. Mol. Ther. 31, 3146\u20133162 (2023).","journal-title":"Mol. Ther."},{"key":"1322_CR48","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1182\/blood.V96.3.785.015k10_785_793","volume":"96","author":"RT Mitsuyasu","year":"2000","unstructured":"Mitsuyasu, R. T. et al. Prolonged survival and tissue trafficking following adoptive transfer of CD4\u03b6 gene-modified autologous CD4+ and CD8+ T cells in human immunodeficiency virus\u2013infected subjects. Blood 96, 785\u2013793 (2000).","journal-title":"Blood"},{"key":"1322_CR49","doi-asserted-by":"publisher","first-page":"2878","DOI":"10.1182\/blood.V84.9.2878.2878","volume":"84","author":"M Roberts","year":"1994","unstructured":"Roberts, M. et al. Targeting of human immunodeficiency virus-infected cells by CD8+ T lymphocytes armed with universal T-cell receptors. Blood 84, 2878\u20132889 (1994).","journal-title":"Blood"},{"key":"1322_CR50","doi-asserted-by":"publisher","first-page":"132ra53","DOI":"10.1126\/scitranslmed.3003761","volume":"4","author":"J Scholler","year":"2012","unstructured":"Scholler, J. et al. Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells. Sci. Transl. Med. 4, 132ra53 (2012).","journal-title":"Sci. Transl. Med."},{"key":"1322_CR51","doi-asserted-by":"publisher","first-page":"e20","DOI":"10.1200\/JCO.2006.05.9964","volume":"24","author":"CHJ Lamers","year":"2006","unstructured":"Lamers, C. H. J. et al. Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. J. Clin. Oncol. 24, e20\u2013e22 (2006).","journal-title":"J. Clin. Oncol."},{"key":"1322_CR52","doi-asserted-by":"publisher","first-page":"6106","DOI":"10.1158\/1078-0432.CCR-06-1183","volume":"12","author":"MH Kershaw","year":"2006","unstructured":"Kershaw, M. H. et al. A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin. Cancer Res. 12, 6106\u20136115 (2006).","journal-title":"Clin. Cancer Res."},{"key":"1322_CR53","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1038\/nm.1882","volume":"14","author":"MA Pule","year":"2008","unstructured":"Pule, M. A. et al. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat. Med. 14, 1264\u20131270 (2008).","journal-title":"Nat. Med."},{"key":"1322_CR54","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/nm827","volume":"9","author":"RJ Brentjens","year":"2003","unstructured":"Brentjens, R. J. et al. Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15. Nat. Med. 9, 279\u2013286 (2003).","journal-title":"Nat. Med."},{"key":"1322_CR55","doi-asserted-by":"publisher","first-page":"3940","DOI":"10.1182\/blood-2011-10-387969","volume":"119","author":"BG Till","year":"2012","unstructured":"Till, B. G. et al. CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results. Blood 119, 3940\u20133950 (2012).","journal-title":"Blood"},{"key":"1322_CR56","doi-asserted-by":"publisher","first-page":"4099","DOI":"10.1182\/blood-2010-04-281931","volume":"116","author":"JN Kochenderfer","year":"2010","unstructured":"Kochenderfer, J. N. et al. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood 116, 4099\u20134102 (2010).","journal-title":"Blood"},{"key":"1322_CR57","doi-asserted-by":"publisher","first-page":"95ra73","DOI":"10.1126\/scitranslmed.3002842","volume":"3","author":"M Kalos","year":"2011","unstructured":"Kalos, M. et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci. Transl. Med. 3, 95ra73 (2011).","journal-title":"Sci. Transl. Med."},{"key":"1322_CR58","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1056\/NEJMoa1103849","volume":"365","author":"DL Porter","year":"2011","unstructured":"Porter, D. L., Levine, B. L., Kalos, M., Bagg, A. & June, C. H. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N. Engl. J. Med. 365, 725\u2013733 (2011). This landmark clinical report demonstrates the massive proliferation and potent antitumour activity of CD19-targeted CAR T cells in a patient with CLL.","journal-title":"N. Engl. J. Med."},{"key":"1322_CR59","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/s41586-021-04390-6","volume":"602","author":"JJ Melenhorst","year":"2022","unstructured":"Melenhorst, J. J. et al. Decade-long leukaemia remissions with persistence of CD4+ CAR T cells. Nature 602, 503\u2013509 (2022). This study provides the first evidence that CAR T cells can persist and maintain functional remission in patients for more than a decade, highlighting their curative potential.","journal-title":"Nature"},{"key":"1322_CR60","doi-asserted-by":"publisher","first-page":"4817","DOI":"10.1182\/blood-2011-04-348540","volume":"118","author":"RJ Brentjens","year":"2011","unstructured":"Brentjens, R. J. et al. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood 118, 4817\u20134828 (2011).","journal-title":"Blood"},{"key":"1322_CR61","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1126\/science.1076514","volume":"298","author":"ME Dudley","year":"2002","unstructured":"Dudley, M. E. et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298, 850\u2013854 (2002).","journal-title":"Science"},{"key":"1322_CR62","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1084\/jem.155.4.1063","volume":"155","author":"RJ North","year":"1982","unstructured":"North, R. J. Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells. J. Exp. Med. 155, 1063\u20131074 (1982).","journal-title":"J. Exp. Med."},{"key":"1322_CR63","doi-asserted-by":"publisher","first-page":"303ra139","DOI":"10.1126\/scitranslmed.aac5415","volume":"7","author":"DL Porter","year":"2015","unstructured":"Porter, D. L. et al. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Sci. Transl. Med. 7, 303ra139 (2015).","journal-title":"Sci. Transl. Med."},{"key":"1322_CR64","doi-asserted-by":"publisher","first-page":"2709","DOI":"10.1182\/blood-2011-10-384388","volume":"119","author":"JN Kochenderfer","year":"2012","unstructured":"Kochenderfer, J. N. et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood 119, 2709\u20132720 (2012).","journal-title":"Blood"},{"key":"1322_CR65","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1200\/JCO.2014.56.2025","volume":"33","author":"JN Kochenderfer","year":"2015","unstructured":"Kochenderfer, J. N. et al. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J. Clin. Oncol. 33, 540\u2013549 (2015).","journal-title":"J. Clin. Oncol."},{"key":"1322_CR66","doi-asserted-by":"publisher","first-page":"177ra38","DOI":"10.1126\/scitranslmed.3005930","volume":"5","author":"RJ Brentjens","year":"2013","unstructured":"Brentjens, R. J. et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci. Transl. Med. 5, 177ra38 (2013).","journal-title":"Sci. Transl. Med."},{"key":"1322_CR67","doi-asserted-by":"publisher","first-page":"224ra25","DOI":"10.1126\/scitranslmed.3008226","volume":"6","author":"ML Davila","year":"2014","unstructured":"Davila, M. L. et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci. Transl. Med. 6, 224ra25 (2014).","journal-title":"Sci. Transl. Med."},{"key":"1322_CR68","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","volume":"371","author":"SL Maude","year":"2014","unstructured":"Maude, S. L. et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N. Engl. J. Med. 371, 1507\u20131517 (2014). This pivotal clinical trial shows high remission rates in paediatric and young adult patients with relapsed\/refractory ALL, establishing the efficacy foundation that led to the registrational ELIANA trial and the first FDA approval of CAR T cell therapy.","journal-title":"N. Engl. J. Med."},{"key":"1322_CR69","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","volume":"385","author":"DW Lee","year":"2015","unstructured":"Lee, D. W. et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet 385, 517\u2013528 (2015).","journal-title":"Lancet"},{"key":"1322_CR70","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1172\/JCI85309","volume":"126","author":"CJ Turtle","year":"2016","unstructured":"Turtle, C. J. et al. CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients. J. Clin. Invest. 126, 2123\u20132138 (2016).","journal-title":"J. Clin. Invest."},{"key":"1322_CR71","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","volume":"368","author":"SA Grupp","year":"2013","unstructured":"Grupp, S. A. et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N. Engl. J. Med. 368, 1509\u20131518 (2013). This landmark report describes the first paediatric patients with relapsed\/refractory ALL treated with CD19-targeted CAR T cells, documenting complete remissions in the two treated children, including one patient who remains in long-term remission to date; crucially, the report introduces the use of the anti-IL-6 receptor antibody tocilizumab that eventually became the standard of care for CRS.","journal-title":"N. Engl. J. Med."},{"key":"1322_CR72","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"Maude, S. L. et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N. Engl. J. Med. 378, 439\u2013448 (2018).","journal-title":"N. Engl. J. Med."},{"key":"1322_CR73","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","volume":"20","author":"KM Cappell","year":"2023","unstructured":"Cappell, K. M. & Kochenderfer, J. N. Long-term outcomes following CAR T cell therapy: what we know so far. Nat. Rev. Clin. Oncol. 20, 359\u2013371 (2023).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1322_CR74","doi-asserted-by":"publisher","first-page":"2671","DOI":"10.1200\/JCO-25-00399","volume":"43","author":"M Kamdar","year":"2025","unstructured":"Kamdar, M. et al. Lisocabtagene maraleucel versus standard of care for second-line relapsed\/refractory large B-cell lymphoma: 3-year follow-up from the randomized, phase III TRANSFORM study. J. Clin. Oncol. 43, 2671\u20132678 (2025).","journal-title":"J. Clin. Oncol."},{"key":"1322_CR75","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1056\/NEJMoa2116133","volume":"386","author":"FL Locke","year":"2022","unstructured":"Locke, F. L. et al. Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma. N. Engl. J. Med. 386, 640\u2013654 (2022). This phase III trial established CAR T cell therapy as a superior second-line standard of care compared with autologous stem cell transplantation for large B cell lymphoma.","journal-title":"N. Engl. J. Med."},{"key":"1322_CR76","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1200\/JCO.21.02370","volume":"41","author":"M Wang","year":"2023","unstructured":"Wang, M. et al. Three-year follow-up of KTE-X19 in patients with relapsed\/refractory mantle cell lymphoma, including high-risk subgroups, in the ZUMA-2 study. J. Clin. Oncol. 41, 555\u2013567 (2023).","journal-title":"J. Clin. Oncol."},{"key":"1322_CR77","doi-asserted-by":"publisher","first-page":"3805","DOI":"10.1200\/JCO.20.01467","volume":"38","author":"KM Cappell","year":"2020","unstructured":"Cappell, K. M. et al. Long-term follow-up of anti-CD19 chimeric antigen receptor T-cell therapy. J. Clin. Oncol. 38, 3805\u20133815 (2020).","journal-title":"J. Clin. Oncol."},{"key":"1322_CR78","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1056\/NEJMc2030164","volume":"384","author":"EA Chong","year":"2021","unstructured":"Chong, E. A., Ruella, M., Schuster, S. J. & Lymphoma Program Investigators at the University of Pennsylvania. Five-year outcomes for refractory B-cell lymphomas with CAR T-cell therapy. N. Engl. J. Med. 384, 673\u2013674 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1322_CR79","first-page":"2307","volume":"141","author":"SS Neelapu","year":"2023","unstructured":"Neelapu, S. S. et al. Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma. Blood 141, 2307\u20132315 (2023).","journal-title":"Blood"},{"key":"1322_CR80","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1016\/S1470-2045(21)00375-2","volume":"22","author":"SJ Schuster","year":"2021","unstructured":"Schuster, S. J. et al. Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol. 22, 1403\u20131415 (2021).","journal-title":"Lancet Oncol."},{"key":"1322_CR81","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1182\/blood.2019000905","volume":"134","author":"AV Hirayama","year":"2019","unstructured":"Hirayama, A. V. et al. High rate of durable complete remission in follicular lymphoma after CD19 CAR-T cell immunotherapy. Blood 134, 636\u2013640 (2019).","journal-title":"Blood"},{"key":"1322_CR82","doi-asserted-by":"publisher","first-page":"2862","DOI":"10.1200\/JCO.19.03237","volume":"38","author":"NV Frey","year":"2020","unstructured":"Frey, N. V. et al. Long-term outcomes from a randomized dose optimization study of chimeric antigen receptor modified T cells in relapsed chronic lymphocytic leukemia. J. Clin. Oncol. 38, 2862\u20132871 (2020).","journal-title":"J. Clin. Oncol."},{"key":"1322_CR83","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1182\/blood.2023020854","volume":"143","author":"JS Abramson","year":"2024","unstructured":"Abramson, J. S. et al. Two-year follow-up of lisocabtagene maraleucel in relapsed or refractory large B-cell lymphoma in TRANSCEND NHL 001. Blood 143, 404\u2013416 (2024).","journal-title":"Blood"},{"key":"1322_CR84","doi-asserted-by":"publisher","first-page":"1794","DOI":"10.1182\/blood.2021011895","volume":"139","author":"T Siddiqi","year":"2022","unstructured":"Siddiqi, T. et al. Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed\/refractory CLL or SLL. Blood 139, 1794\u20131806 (2022).","journal-title":"Blood"},{"key":"1322_CR85","doi-asserted-by":"publisher","first-page":"3573","DOI":"10.1200\/JCO-25-00668","volume":"43","author":"SS Neelapu","year":"2025","unstructured":"Neelapu, S. S. et al. Five-year follow-up analysis of ZUMA-5: axicabtagene ciloleucel in relapsed\/refractory indolent non-Hodgkin lymphoma. J. Clin. Oncol. 43, 3573\u20133577 (2025).","journal-title":"J. Clin. Oncol."},{"key":"1322_CR86","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1182\/blood.2023021567","volume":"143","author":"M Dreyling","year":"2024","unstructured":"Dreyling, M. et al. Durable response after tisagenlecleucel in adults with relapsed\/refractory follicular lymphoma: ELARA trial update. Blood 143, 1713\u20131725 (2024).","journal-title":"Blood"},{"key":"1322_CR87","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1056\/NEJMoa2301665","volume":"389","author":"JR Westin","year":"2023","unstructured":"Westin, J. R. et al. Survival with axicabtagene ciloleucel in large B-cell lymphoma. N. Engl. J. Med. 389, 148\u2013157 (2023).","journal-title":"N. Engl. J. Med."},{"key":"1322_CR88","doi-asserted-by":"publisher","first-page":"4633","DOI":"10.1182\/blood-2024-200840","volume":"144","author":"T Siddiqi","year":"2024","unstructured":"Siddiqi, T. et al. Lisocabtagene maraleucel (liso-cel) in patients (pts) with relapsed or refractory (R\/R) chronic lymphocytic leukemia (CLL)\/small lymphocytic lymphoma (SLL): updated follow-up of transcend CLL 004. Blood 144, 4633 (2024).","journal-title":"Blood"},{"key":"1322_CR89","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1097\/01.HS9.0000843344.19780.98","volume":"6","author":"S Rives","year":"2022","unstructured":"Rives, S. et al. S112: tisagenlecleucel in pediatric and young adult patients (pts) with relapsed\/refractory (R\/R) B-cell acute lymphoblastic leukemia (B-ALL): final analyses from the ELIANA study. HemaSphere 6, 13\u201314 (2022).","journal-title":"HemaSphere"},{"key":"1322_CR90","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1038\/s41375-025-02532-7","volume":"39","author":"BD Shah","year":"2025","unstructured":"Shah, B. D. et al. Three-year analysis of adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3. Leukemia 39, 1058\u20131068 (2025).","journal-title":"Leukemia"},{"key":"1322_CR91","doi-asserted-by":"publisher","first-page":"2766","DOI":"10.1200\/JCO-25-00760","volume":"43","author":"S Jagannath","year":"2025","unstructured":"Jagannath, S. et al. Long-term (\u22655-year) remission and survival after treatment with ciltacabtagene autoleucel in CARTITUDE-1 patients with relapsed\/refractory multiple myeloma. J. Clin. Oncol. 43, 2766\u20132771 (2025). This long-term follow-up confirms the unprecedented durability of responses to BCMA-targeted CAR T cell therapy in heavily pretreated multiple myeloma.","journal-title":"J. Clin. Oncol."},{"key":"1322_CR92","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1111\/imr.12821","volume":"292","author":"E Meffre","year":"2019","unstructured":"Meffre, E. & O\u2019Connor, K. C. Impaired B-cell tolerance checkpoints promote the development of autoimmune diseases and pathogenic autoantibodies. Immunol. Rev. 292, 90\u2013101 (2019).","journal-title":"Immunol. Rev."},{"key":"1322_CR93","doi-asserted-by":"publisher","first-page":"eaav1648","DOI":"10.1126\/scitranslmed.aav1648","volume":"11","author":"R Kansal","year":"2019","unstructured":"Kansal, R. et al. Sustained B cell depletion by CD19-targeted CAR T cells is a highly effective treatment for murine lupus. Sci. Transl. Med. 11, eaav1648 (2019).","journal-title":"Sci. Transl. Med."},{"key":"1322_CR94","doi-asserted-by":"publisher","first-page":"1896","DOI":"10.1038\/s41423-020-0472-1","volume":"18","author":"X Jin","year":"2021","unstructured":"Jin, X. et al. Therapeutic efficacy of anti-CD19 CAR-T cells in a mouse model of systemic lupus erythematosus. Cell. Mol. Immunol. 18, 1896\u20131903 (2021).","journal-title":"Cell. Mol. Immunol."},{"key":"1322_CR95","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1056\/NEJMc2107725","volume":"385","author":"D Mougiakakos","year":"2021","unstructured":"Mougiakakos, D. et al. CD19-targeted CAR T cells in refractory systemic lupus erythematosus. N. Engl. J. Med. 385, 567\u2013569 (2021). This seminal case report documents the first-in-human application of CD19-targeted CAR T cells for severe SLE, proving that the therapy could induce rapid, drug-free remission in autoimmune disease.","journal-title":"N. Engl. J. Med."},{"key":"1322_CR96","doi-asserted-by":"publisher","first-page":"2124","DOI":"10.1038\/s41591-022-02017-5","volume":"28","author":"A Mackensen","year":"2022","unstructured":"Mackensen, A. et al. Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus. Nat. Med. 28, 2124\u20132132 (2022).","journal-title":"Nat. Med."},{"key":"1322_CR97","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1136\/ard-2023-223952","volume":"82","author":"C Bergmann","year":"2023","unstructured":"Bergmann, C. et al. Treatment of a patient with severe systemic sclerosis (SSc) using CD19-targeted CAR T cells. Ann. Rheum. Dis. 82, 1117\u20131120 (2023).","journal-title":"Ann. Rheum. Dis."},{"key":"1322_CR98","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1136\/ard-2023-225174","volume":"83","author":"W Merkt","year":"2024","unstructured":"Merkt, W. et al. Third-generation CD19.CAR-T cell-containing combination therapy in Scl70+ systemic sclerosis. Ann. Rheum. Dis. 83, 543\u2013546 (2024).","journal-title":"Ann. Rheum. Dis."},{"key":"1322_CR99","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1016\/S1474-4422(23)00375-7","volume":"22","author":"A Haghikia","year":"2023","unstructured":"Haghikia, A. et al. Anti-CD19 CAR T cells for refractory myasthenia gravis. Lancet Neurol. 22, 1104\u20131105 (2023).","journal-title":"Lancet Neurol."},{"key":"1322_CR100","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/j.medj.2024.03.002","volume":"5","author":"F Fischbach","year":"2024","unstructured":"Fischbach, F. et al. CD19-targeted chimeric antigen receptor T cell therapy in two patients with multiple sclerosis. Med 5, 550\u2013558.e2 (2024).","journal-title":"Med"},{"key":"1322_CR101","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1016\/S0140-6736(23)00023-5","volume":"401","author":"F M\u00fcller","year":"2023","unstructured":"M\u00fcller, F. et al. CD19-targeted CAR T cells in refractory antisynthetase syndrome. Lancet 401, 815\u2013818 (2023).","journal-title":"Lancet"},{"key":"1322_CR102","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1001\/jama.2023.8753","volume":"329","author":"A-C Pecher","year":"2023","unstructured":"Pecher, A.-C. et al. CD19-targeting CAR T cells for myositis and interstitial lung disease associated with antisynthetase syndrome. JAMA 329, 2154\u20132162 (2023).","journal-title":"JAMA"},{"key":"1322_CR103","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1056\/NEJMoa2308917","volume":"390","author":"F M\u00fcller","year":"2024","unstructured":"M\u00fcller, F. et al. CD19 CAR T-cell therapy in autoimmune disease\u2014a case series with follow-up. N. Engl. J. Med. 390, 687\u2013700 (2024). This work is one of the earliest large case series showing that a CD19-targeted CAR T cell-induced immune \u2018reset\u2019 can be safe, highly effective and potentially durable across several refractory autoimmune diseases.","journal-title":"N. Engl. J. Med."},{"key":"1322_CR104","doi-asserted-by":"publisher","first-page":"100749","DOI":"10.1016\/j.medj.2025.100749","volume":"6","author":"D Wang","year":"2025","unstructured":"Wang, D. et al. Allogeneic CD19-targeted CAR-T therapy in refractory systemic lupus erythematosus achieved durable remission. Med 6, 100749 (2025).","journal-title":"Med"},{"key":"1322_CR105","doi-asserted-by":"publisher","first-page":"2426","DOI":"10.1016\/j.ymthe.2025.03.040","volume":"33","author":"C Georgiadis","year":"2025","unstructured":"Georgiadis, C., Preece, R. & Qasim, W. Clinical development of allogeneic chimeric antigen receptor \u03b1\u03b2-T cells. Mol. Ther. 33, 2426\u20132440 (2025).","journal-title":"Mol. Ther."},{"key":"1322_CR106","doi-asserted-by":"publisher","first-page":"4890","DOI":"10.1016\/j.cell.2024.06.027","volume":"187","author":"X Wang","year":"2024","unstructured":"Wang, X. et al. Allogeneic CD19-targeted CAR-T therapy in patients with severe myositis and systemic sclerosis. Cell 187, 4890\u20134904.e9 (2024).","journal-title":"Cell"},{"key":"1322_CR107","doi-asserted-by":"publisher","first-page":"3713","DOI":"10.1038\/s41591-025-03899-x","volume":"31","author":"X Wang","year":"2025","unstructured":"Wang, X. et al. Allogeneic CD19-targeting T cells for treatment-refractory systemic lupus erythematosus: a phase 1 trial. Nat. Med. 31, 3713\u20133724 (2025).","journal-title":"Nat. Med."},{"key":"1322_CR108","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1056\/NEJMc2509522","volume":"393","author":"Q Wang","year":"2025","unstructured":"Wang, Q. et al. In vivo CD19 CAR T-cell therapy for refractory systemic lupus erythematosus. N. Engl. J. Med. 393, 1542\u20131544 (2025).","journal-title":"N. Engl. J. Med."},{"key":"1322_CR109","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41392-022-01278-3","volume":"8","author":"C Qin","year":"2023","unstructured":"Qin, C. et al. Anti-BCMA CAR T-cell therapy CT103A in relapsed or refractory AQP4-IgG seropositive neuromyelitis optica spectrum disorders: phase 1 trial interim results. Signal. Transduct. Target. Ther. 8, 5 (2023).","journal-title":"Signal. Transduct. Target. Ther."},{"key":"1322_CR110","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2315990121","volume":"121","author":"C Qin","year":"2024","unstructured":"Qin, C. et al. Single-cell analysis of refractory anti-SRP necrotizing myopathy treated with anti-BCMA CAR-T cell therapy. Proc. Natl Acad. Sci. USA 121, e2315990121 (2024).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1322_CR111","doi-asserted-by":"publisher","first-page":"6414","DOI":"10.1016\/j.cell.2025.09.020","volume":"188","author":"C Qin","year":"2025","unstructured":"Qin, C. et al. Anti-BCMA CAR-T therapy in patients with progressive multiple sclerosis. Cell 188, 6414\u20136423.e11 (2025).","journal-title":"Cell"},{"key":"1322_CR112","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/S1474-4422(23)00194-1","volume":"22","author":"V Granit","year":"2023","unstructured":"Granit, V. et al. Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non-randomised phase 1b\/2a study. Lancet Neurol. 22, 578\u2013590 (2023).","journal-title":"Lancet Neurol."},{"key":"1322_CR113","doi-asserted-by":"publisher","first-page":"3725","DOI":"10.1038\/s41591-025-03937-8","volume":"31","author":"J Feng","year":"2025","unstructured":"Feng, J. et al. Co-infusion of CD19-targeting and BCMA-targeting CAR-T cells for treatment-refractory systemic lupus erythematosus: a phase 1 trial. Nat. Med. 31, 3725\u20133736 (2025).","journal-title":"Nat. Med."},{"key":"1322_CR114","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1136\/ard-2024-225785","volume":"83","author":"W Wang","year":"2024","unstructured":"Wang, W. et al. BCMA\u2013CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial. Ann. Rheum. Dis. 83, 1304\u20131314 (2024).","journal-title":"Ann. Rheum. Dis."},{"key":"1322_CR115","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-46448-9","volume":"15","author":"M Doglio","year":"2024","unstructured":"Doglio, M. et al. Regulatory T cells expressing CD19-targeted chimeric antigen receptor restore homeostasis in systemic lupus erythematosus. Nat. Commun. 15, 2542 (2024).","journal-title":"Nat. Commun."},{"key":"1322_CR116","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1126\/science.aaf6756","volume":"353","author":"CT Ellebrecht","year":"2016","unstructured":"Ellebrecht, C. T. et al. Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease. Science 353, 179\u2013184 (2016).","journal-title":"Science"},{"key":"1322_CR117","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1038\/s41587-022-01637-z","volume":"41","author":"S Oh","year":"2023","unstructured":"Oh, S. et al. Precision targeting of autoantigen-specific B cells in muscle-specific tyrosine kinase myasthenia gravis with chimeric autoantibody receptor T cells. Nat. Biotechnol. 41, 1229\u20131238 (2023).","journal-title":"Nat. Biotechnol."},{"key":"1322_CR118","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1182\/blood.2024024063","volume":"145","author":"S Haubner","year":"2025","unstructured":"Haubner, S., Subklewe, M. & Sadelain, M. Honing CAR T cells to tackle acute myeloid leukemia. Blood 145, 1113\u20131125 (2025).","journal-title":"Blood"},{"key":"1322_CR119","doi-asserted-by":"publisher","first-page":"3282","DOI":"10.1038\/s41375-021-01232-2","volume":"35","author":"FP Tambaro","year":"2021","unstructured":"Tambaro, F. P. et al. Autologous CD33-CAR-T cells for treatment of relapsed\/refractory acute myelogenous leukemia. Leukemia 35, 3282\u20133286 (2021).","journal-title":"Leukemia"},{"key":"1322_CR120","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1182\/blood-2023-179667","volume":"142","author":"NN Shah","year":"2023","unstructured":"Shah, N. N. et al. CD33 CAR T-cells (CD33CART) for children and young adults with relapsed\/refractory AML: dose-escalation results from a phase I\/II multicenter trial. Blood 142, 771 (2023).","journal-title":"Blood"},{"key":"1322_CR121","doi-asserted-by":"publisher","first-page":"4584","DOI":"10.1182\/blood-2022-170201","volume":"140","author":"S Naik","year":"2022","unstructured":"Naik, S. et al. Safety and anti-leukemic activity of CD123-CAR T cells in pediatric patients with AML: preliminary results from a phase 1 trial. Blood 140, 4584\u20134585 (2022).","journal-title":"Blood"},{"key":"1322_CR122","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1182\/blood.V130.Suppl_1.811.811","volume":"130","author":"L Budde","year":"2017","unstructured":"Budde, L. et al. Remissions of acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm following treatment with CD123-specific CAR T cells: a first-in-human clinical trial. Blood 130, 811\u2013811 (2017).","journal-title":"Blood"},{"key":"1322_CR123","doi-asserted-by":"publisher","first-page":"3697","DOI":"10.1038\/s41591-024-03271-5","volume":"30","author":"AS Bhagwat","year":"2024","unstructured":"Bhagwat, A. S. et al. Cytokine-mediated CAR T therapy resistance in AML. Nat. Med. 30, 3697\u20133708 (2024).","journal-title":"Nat. Med."},{"key":"1322_CR124","doi-asserted-by":"publisher","first-page":"2371","DOI":"10.1182\/blood-2022-169928","volume":"140","author":"DA Sallman","year":"2022","unstructured":"Sallman, D. A. et al. Ameli-01: a phase I trial of UCART123v1.2, an anti-CD123 allogeneic CAR-T cell product, in adult patients with relapsed or refractory (R\/R) CD123+ acute myeloid leukemia (AML). Blood 140, 2371\u20132373 (2022).","journal-title":"Blood"},{"key":"1322_CR125","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1007\/s00277-024-05617-y","volume":"103","author":"Y Zhao","year":"2024","unstructured":"Zhao, Y. et al. Modified EASIX scores predict severe CRS\/ICANS in patients with acute myeloid leukemia following CLL1 CAR-T cell therapy. Ann. Hematol. 103, 969\u2013980 (2024).","journal-title":"Ann. Hematol."},{"key":"1322_CR126","doi-asserted-by":"publisher","first-page":"2596","DOI":"10.1038\/s41375-022-01703-0","volume":"36","author":"H Zhang","year":"2022","unstructured":"Zhang, H. et al. Characteristics of anti-CLL1 based CAR-T therapy for children with relapsed or refractory acute myeloid leukemia: the multi-center efficacy and safety interim analysis. Leukemia 36, 2596\u20132604 (2022).","journal-title":"Leukemia"},{"key":"1322_CR127","doi-asserted-by":"publisher","first-page":"9655","DOI":"10.1002\/cam4.5916","volume":"12","author":"K Pei","year":"2023","unstructured":"Pei, K. et al. Anti-CLL1 -based CAR T -cells with 4-1-BB or CD28\/CD27 stimulatory domains in treating childhood refractory\/relapsed acute myeloid leukemia. Cancer Med. 12, 9655\u20139661 (2023).","journal-title":"Cancer Med."},{"key":"1322_CR128","first-page":"615","volume":"12","author":"Y-J Ma","year":"2022","unstructured":"Ma, Y.-J. et al. Successful application of PD-1 knockdown CLL-1 CAR-T therapy in two AML patients with post-transplant relapse and failure of anti-CD38 CAR-T cell treatment. Am. J. Cancer Res. 12, 615\u2013621 (2022).","journal-title":"Am. J. Cancer Res."},{"key":"1322_CR129","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1038\/mt.2014.164","volume":"23","author":"Q Wang","year":"2015","unstructured":"Wang, Q. et al. Treatment of CD33-directed chimeric antigen receptor-modified T cells in one patient with relapsed and refractory acute myeloid leukemia. Mol. Ther. 23, 184\u2013191 (2015).","journal-title":"Mol. Ther."},{"key":"1322_CR130","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1182\/bloodadvances.2023012263","volume":"9","author":"N Maciocia","year":"2025","unstructured":"Maciocia, N., Wade, B. & Maciocia, P. CAR T-cell therapies for T-cell malignancies: does cellular immunotherapy represent the best chance of cure? Blood Adv. 9, 913\u2013923 (2025).","journal-title":"Blood Adv."},{"key":"1322_CR131","first-page":"321","volume":"140","author":"P Lu","year":"2022","unstructured":"Lu, P. et al. Naturally selected CD7 CAR-T therapy without genetic manipulations for T-ALL\/LBL: first-in-human phase 1 clinical trial. Blood 140, 321\u2013334 (2022).","journal-title":"Blood"},{"key":"1322_CR132","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.1002\/ajh.27094","volume":"98","author":"X Zhang","year":"2023","unstructured":"Zhang, X. et al. Analysis of 60 patients with relapsed or refractory T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma treated with CD7-targeted chimeric antigen receptor-T cell therapy. Am. J. Hematol. 98, 1898\u20131908 (2023).","journal-title":"Am. J. Hematol."},{"key":"1322_CR133","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.1016\/j.ymthe.2024.09.006","volume":"33","author":"L Zhao","year":"2025","unstructured":"Zhao, L. et al. Autologous CD7 CAR-T cells generated without T cell pre-selection in pediatric patients with relapsed\/refractory T-ALL: a phase I trial. Mol. Ther. 33, 2753\u20132767 (2025).","journal-title":"Mol. Ther."},{"key":"1322_CR134","doi-asserted-by":"publisher","first-page":"2830","DOI":"10.1158\/1078-0432.CCR-21-4097","volume":"28","author":"M Zhang","year":"2022","unstructured":"Zhang, M. et al. Autologous nanobody-derived fratricide-resistant CD7-CAR T-cell therapy for patients with relapsed and refractory T-cell acute lymphoblastic leukemia\/lymphoma. Clin. Cancer Res. 28, 2830\u20132843 (2022).","journal-title":"Clin. Cancer Res."},{"key":"1322_CR135","doi-asserted-by":"publisher","first-page":"3687","DOI":"10.1038\/s41591-024-03228-8","volume":"30","author":"BLZ Oh","year":"2024","unstructured":"Oh, B. L. Z. et al. Fratricide-resistant CD7-CAR T cells in T-ALL. Nat. Med. 30, 3687\u20133696 (2024).","journal-title":"Nat. Med."},{"key":"1322_CR136","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13045-023-01427-3","volume":"16","author":"Y Tan","year":"2023","unstructured":"Tan, Y. et al. Long-term follow-up of donor-derived CD7 CAR T-cell therapy in patients with T-cell acute lymphoblastic leukemia. J. Hematol. Oncol. 16, 34 (2023).","journal-title":"J. Hematol. Oncol."},{"key":"1322_CR137","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1038\/s41422-022-00721-y","volume":"32","author":"Y Hu","year":"2022","unstructured":"Hu, Y. et al. Genetically modified CD7-targeting allogeneic CAR-T cell therapy with enhanced efficacy for relapsed\/refractory CD7-positive hematological malignancies: a phase I clinical study. Cell Res. 32, 995\u20131007 (2022).","journal-title":"Cell Res."},{"key":"1322_CR138","doi-asserted-by":"publisher","first-page":"2176","DOI":"10.1038\/s41375-023-02018-4","volume":"37","author":"S Li","year":"2023","unstructured":"Li, S. et al. CD7 targeted \u2018off-the-shelf\u2019 CAR-T demonstrates robust in vivo expansion and high efficacy in the treatment of patients with relapsed and refractory T cell malignancies. Leukemia 37, 2176\u20132186 (2023).","journal-title":"Leukemia"},{"key":"1322_CR139","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1182\/blood.2025028387","volume":"146","author":"A Ghobadi","year":"2025","unstructured":"Ghobadi, A. et al. Phase 1\/2 trial of anti-CD7 allogeneic WU-CART-007 for patients with relapsed\/refractory T-cell malignancies. Blood 146, 1163\u20131173 (2025).","journal-title":"Blood"},{"key":"1322_CR140","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1056\/NEJMoa2313812","volume":"390","author":"Y Hu","year":"2024","unstructured":"Hu, Y. et al. Sequential CD7 CAR T-cell therapy and allogeneic HSCT without GVHD prophylaxis. N. Engl. J. Med. 390, 1467\u20131480 (2024).","journal-title":"N. Engl. J. Med."},{"key":"1322_CR141","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1056\/NEJMoa2300709","volume":"389","author":"R Chiesa","year":"2023","unstructured":"Chiesa, R. et al. Base-edited CAR7 T cells for relapsed T-cell acute lymphoblastic leukemia. N. Engl. J. Med. 389, 899\u2013910 (2023). This work is the first clinical application of base-editing technology to generate multiplexed, universal CAR T cells, demonstrating the feasibility of \u2018off-the-shelf\u2019 therapies.","journal-title":"N. Engl. J. Med."},{"key":"1322_CR142","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1182\/blood.2022015825","volume":"140","author":"C Diorio","year":"2022","unstructured":"Diorio, C. et al. Cytosine base editing enables quadruple-edited allogeneic CART cells for T-ALL. Blood 140, 619\u2013629 (2022).","journal-title":"Blood"},{"key":"1322_CR143","doi-asserted-by":"publisher","first-page":"7002","DOI":"10.1200\/JCO.2023.41.16_suppl.7002","volume":"41","author":"LC Hill","year":"2023","unstructured":"Hill, L. C. et al. Enhanced anti-tumor activity of CD5 CAR T cells manufactured with tyrosine kinase inhibitors in patients with relapsed\/refractory T-ALL. J. Clin. Oncol. 41, 7002 (2023).","journal-title":"J. Clin. Oncol."},{"key":"1322_CR144","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1038\/s41591-024-03282-2","volume":"31","author":"J Pan","year":"2025","unstructured":"Pan, J. et al. Allogeneic CD5-specific CAR-T therapy for relapsed\/refractory T-ALL: a phase 1 trial. Nat. Med. 31, 126\u2013136 (2025).","journal-title":"Nat. Med."},{"key":"1322_CR145","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1182\/blood.2023022204","volume":"143","author":"LC Hill","year":"2024","unstructured":"Hill, L. C. et al. Antitumor efficacy and safety of unedited autologous CD5.CAR T cells in relapsed\/refractory mature T-cell lymphomas. Blood 143, 1231\u20131241 (2024).","journal-title":"Blood"},{"key":"1322_CR146","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01082-y","volume":"14","author":"H Lin","year":"2024","unstructured":"Lin, H. et al. Anti-CD5 CAR-T cells with a tEGFR safety switch exhibit potent toxicity control. Blood Cancer J. 14, 98 (2024).","journal-title":"Blood Cancer J."},{"key":"1322_CR147","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1038\/s41591-024-03326-7","volume":"31","author":"K Cwynarski","year":"2025","unstructured":"Cwynarski, K. et al. TRBC1-CAR T cell therapy in peripheral T cell lymphoma: a phase 1\/2 trial. Nat. Med. 31, 137\u2013143 (2025).","journal-title":"Nat. Med."},{"key":"1322_CR148","doi-asserted-by":"publisher","first-page":"6854","DOI":"10.1182\/blood-2023-180111","volume":"142","author":"R Assi","year":"2023","unstructured":"Assi, R. et al. Phase I first-in-human study on the feasibility, safety, and antitumor activity of CD4-redirected chimeric antigen receptor (CAR) T-cell therapy in patients with CD4+ T-cell malignancies (TCM). Blood 142, 6854\u20136854 (2023).","journal-title":"Blood"},{"key":"1322_CR149","doi-asserted-by":"publisher","first-page":"3462","DOI":"10.1172\/JCI94306","volume":"127","author":"CA Ramos","year":"2017","unstructured":"Ramos, C. A. et al. Clinical and immunological responses after CD30-specific chimeric antigen receptor-redirected lymphocytes. J. Clin. Invest. 127, 3462\u20133471 (2017).","journal-title":"J. Clin. Invest."},{"key":"1322_CR150","doi-asserted-by":"publisher","first-page":"e358","DOI":"10.1016\/S2352-3026(24)00064-4","volume":"11","author":"NS Grover","year":"2024","unstructured":"Grover, N. S. et al. Anti-CD30 CAR T cells as consolidation after autologous haematopoietic stem-cell transplantation in patients with high-risk CD30+ lymphoma: a phase 1 study. Lancet Haematol. 11, e358\u2013e367 (2024).","journal-title":"Lancet Haematol."},{"key":"1322_CR151","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/S1470-2045(24)00508-4","volume":"26","author":"SP Iyer","year":"2025","unstructured":"Iyer, S. P. et al. Safety and activity of CTX130, a CD70-targeted allogeneic CRISPR\u2013Cas9-engineered CAR T-cell therapy, in patients with relapsed or refractory T-cell malignancies (COBALT-LYM): a single-arm, open-label, phase 1, dose-escalation study. Lancet Oncol. 26, 110\u2013122 (2025).","journal-title":"Lancet Oncol."},{"key":"1322_CR152","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1182\/blood.2024024104","volume":"144","author":"MJ Frigault","year":"2024","unstructured":"Frigault, M. J. et al. Phase 1 study of CAR-37 T cells in patients with relapsed or refractory CD37+ lymphoid malignancies. Blood 144, 1153\u20131167 (2024).","journal-title":"Blood"},{"key":"1322_CR153","doi-asserted-by":"publisher","first-page":"2656","DOI":"10.1200\/JCO.21.00612","volume":"39","author":"AA Sarnaik","year":"2021","unstructured":"Sarnaik, A. A. et al. Lifileucel, a tumor-infiltrating lymphocyte therapy, in metastatic melanoma. J. Clin. Oncol. 39, 2656\u20132666 (2021).","journal-title":"J. Clin. Oncol."},{"key":"1322_CR154","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1016\/S0140-6736(24)00319-2","volume":"403","author":"SP D\u2019Angelo","year":"2024","unstructured":"D\u2019Angelo, S. P. et al. Afamitresgene autoleucel for advanced synovial sarcoma and myxoid round cell liposarcoma (SPEARHEAD-1): an international, open-label, phase 2 trial. Lancet 403, 1460\u20131471 (2024).","journal-title":"Lancet"},{"key":"1322_CR155","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1038\/s41587-024-02446-2","volume":"43","author":"U Uslu","year":"2025","unstructured":"Uslu, U. & June, C. H. Beyond the blood: expanding CAR T cell therapy to solid tumors. Nat. Biotechnol. 43, 506\u2013515 (2025).","journal-title":"Nat. Biotechnol."},{"key":"1322_CR156","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1038\/s41586-023-05707-3","volume":"614","author":"L Labanieh","year":"2023","unstructured":"Labanieh, L. & Mackall, C. L. CAR immune cells: design principles, resistance and the next generation. Nature 614, 635\u2013648 (2023).","journal-title":"Nature"},{"key":"1322_CR157","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1056\/NEJMoa2210859","volume":"388","author":"F Del Bufalo","year":"2023","unstructured":"Del Bufalo, F. et al. GD2-CART01 for relapsed or refractory high-risk neuroblastoma. N. Engl. J. Med. 388, 1284\u20131295 (2023).","journal-title":"N. Engl. J. Med."},{"key":"1322_CR158","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.1038\/s41591-024-03037-z","volume":"30","author":"C Qi","year":"2024","unstructured":"Qi, C. et al. Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial final results. Nat. Med. 30, 2224\u20132234 (2024).","journal-title":"Nat. Med."},{"key":"1322_CR159","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1016\/S0140-6736(25)00860-8","volume":"405","author":"C Qi","year":"2025","unstructured":"Qi, C. et al. Claudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician\u2019s choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial. Lancet 405, 2049\u20132060 (2025). This first randomized clinical trial of CAR T cell therapy in solid tumours shows that claudin 18.2-targeted CAR T cell therapy (satri-cel) markedly improved the objective response rate and progression-free survival compared with physician\u2019s choice chemotherapy in patients with advanced gastric or gastro-oesophageal junction cancer who had been\u00a0previously treated, supporting the clinical feasibility of CAR T cell therapy in solid tumours.","journal-title":"Lancet"},{"key":"1322_CR160","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1038\/s43018-024-00749-6","volume":"5","author":"M Hegde","year":"2024","unstructured":"Hegde, M. et al. Autologous HER2-specific CAR T cells after lymphodepletion for advanced sarcoma: a phase 1 trial. Nat. Cancer 5, 880\u2013894 (2024).","journal-title":"Nat. Cancer"},{"key":"1322_CR161","doi-asserted-by":"publisher","first-page":"2844","DOI":"10.1038\/s41591-023-02612-0","volume":"29","author":"A Mackensen","year":"2023","unstructured":"Mackensen, A. et al. CLDN6-specific CAR-T cells plus amplifying RNA vaccine in relapsed or refractory solid tumors: the phase 1 BNT211-01 trial. Nat. Med. 29, 2844\u20132853 (2023).","journal-title":"Nat. Med."},{"key":"1322_CR162","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1038\/s41586-024-08261-8","volume":"637","author":"D Steffin","year":"2025","unstructured":"Steffin, D. et al. Interleukin-15-armoured GPC3 CAR T cells for patients with solid cancers. Nature 637, 940\u2013946 (2025). This study shows that \u2018armouring\u2019 GPC3-targeted CAR T cells with IL-15 enhances their in vivo proliferation and persistence, enabling effective objective responses in patients with difficult-to-treat solid tumours.","journal-title":"Nature"},{"key":"1322_CR163","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1038\/s41591-024-02875-1","volume":"30","author":"CE Brown","year":"2024","unstructured":"Brown, C. E. et al. Locoregional delivery of IL-13R\u03b12-targeting CAR-T cells in recurrent high-grade glioma: a phase 1 trial. Nat. Med. 30, 1001\u20131012 (2024).","journal-title":"Nat. Med."},{"key":"1322_CR164","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1056\/NEJMoa2314390","volume":"390","author":"BD Choi","year":"2024","unstructured":"Choi, B. D. et al. Intraventricular CARv3-TEAM-E T cells in recurrent glioblastoma. N. Engl. J. Med. 390, 1290\u20131298 (2024).","journal-title":"N. Engl. J. Med."},{"key":"1322_CR165","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1038\/s41591-024-02893-z","volume":"30","author":"SJ Bagley","year":"2024","unstructured":"Bagley, S. J. et al. Intrathecal bivalent CAR T cells targeting EGFR and IL13R\u03b12 in recurrent glioblastoma: phase 1 trial interim results. Nat. Med. 30, 1320\u20131329 (2024).","journal-title":"Nat. Med."},{"key":"1322_CR166","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1038\/s41586-024-08171-9","volume":"637","author":"M Monje","year":"2025","unstructured":"Monje, M. et al. Intravenous and intracranial GD2-CAR T cells for H3K27M+ diffuse midline gliomas. Nature 637, 708\u2013715 (2025). This major breakthrough study shows that GD2-targeted CAR T cells can mediate meaningful clinical and radiographic responses in fatal diffuse midline gliomas.","journal-title":"Nature"},{"key":"1322_CR167","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1038\/s41586-022-04489-4","volume":"603","author":"RG Majzner","year":"2022","unstructured":"Majzner, R. G. et al. GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas. Nature 603, 934\u2013941 (2022).","journal-title":"Nature"},{"key":"1322_CR168","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-59021-9","volume":"16","author":"K Sek","year":"2025","unstructured":"Sek, K. et al. Tumor site-directed A1R expression enhances CAR T cell function and improves efficacy against solid tumors. Nat. Commun. 16, 6123 (2025).","journal-title":"Nat. Commun."},{"key":"1322_CR169","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1038\/s43018-025-01009-x","volume":"6","author":"F Yi","year":"2025","unstructured":"Yi, F. et al. CAR-engineered lymphocyte persistence is governed by a FAS ligand\u2013FAS autoregulatory circuit. Nat. Cancer 6, 1638\u20131655 (2025).","journal-title":"Nat. Cancer"},{"key":"1322_CR170","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1038\/s41586-024-07962-4","volume":"634","author":"B Feng","year":"2024","unstructured":"Feng, B. et al. The type 2 cytokine Fc-IL-4 revitalizes exhausted CD8+ T cells against cancer. Nature 634, 712\u2013720 (2024).","journal-title":"Nature"},{"key":"1322_CR171","doi-asserted-by":"publisher","first-page":"5697","DOI":"10.1158\/0008-5472.CAN-11-0103","volume":"71","author":"M Chmielewski","year":"2011","unstructured":"Chmielewski, M., Kopecky, C., Hombach, A. A. & Abken, H. IL-12 release by engineered T cells expressing chimeric antigen receptors can effectively muster an antigen-independent macrophage response on tumor cells that have shut down tumor antigen expression. Cancer Res. 71, 5697\u20135706 (2011).","journal-title":"Cancer Res."},{"key":"1322_CR172","doi-asserted-by":"publisher","first-page":"3025","DOI":"10.1016\/j.celrep.2017.09.002","volume":"20","author":"B Hu","year":"2017","unstructured":"Hu, B. et al. Augmentation of antitumor immunity by human and mouse CAR T cells secreting IL-18. Cell Rep. 20, 3025\u20133033 (2017).","journal-title":"Cell Rep."},{"key":"1322_CR173","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1038\/s41586-024-07300-8","volume":"629","author":"AE Doan","year":"2024","unstructured":"Doan, A. E. et al. FOXO1 is a master regulator of memory programming in CAR T cells. Nature 629, 211\u2013218 (2024). This study identifies FOXO1 as a crucial transcription factor for maintaining T cell stemness, offering a new target to improve the durability of CAR T cell therapies.","journal-title":"Nature"},{"key":"1322_CR174","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/s41586-024-07242-1","volume":"629","author":"JD Chan","year":"2024","unstructured":"Chan, J. D. et al. FOXO1 enhances CAR T cell stemness, metabolic fitness and efficacy. Nature 629, 201\u2013210 (2024). Together with Doan et al. (2024), this study independently identifies FOXO1 as a crucial regulator of T cell memory and metabolic fitness, demonstrating that its overexpression effectively uncouples antitumour activity from T cell exhaustion.","journal-title":"Nature"},{"key":"1322_CR175","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/s41586-019-1805-z","volume":"576","author":"RC Lynn","year":"2019","unstructured":"Lynn, R. C. et al. c-Jun overexpression in CAR T cells induces exhaustion resistance. Nature 576, 293\u2013300 (2019). This study identifies a defect in the AP-1\u00a0transcription factor complex as a key driver of CAR T cell exhaustion and showed that overexpression of JUN renders T cells resistant to dysfunction and enhances antitumour efficacy.","journal-title":"Nature"},{"key":"1322_CR176","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1016\/j.ccell.2022.09.013","volume":"40","author":"X Zhang","year":"2022","unstructured":"Zhang, X. et al. Depletion of BATF in CAR-T cells enhances antitumor activity by inducing resistance against exhaustion and formation of central memory cells. Cancer Cell 40, 1407\u20131422.e7 (2022).","journal-title":"Cancer Cell"},{"key":"1322_CR177","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1038\/s41590-021-00964-8","volume":"22","author":"H Seo","year":"2021","unstructured":"Seo, H. et al. BATF and IRF4 cooperate to counter exhaustion in tumor-infiltrating CAR T cells. Nat. Immunol. 22, 983\u2013995 (2021).","journal-title":"Nat. Immunol."},{"key":"1322_CR178","doi-asserted-by":"publisher","first-page":"2156","DOI":"10.1182\/blood.2021012714","volume":"139","author":"T Yoshikawa","year":"2022","unstructured":"Yoshikawa, T. et al. Genetic ablation of PRDM1 in antitumor T cells enhances therapeutic efficacy of adoptive immunotherapy. Blood 139, 2156\u20132172 (2022).","journal-title":"Blood"},{"key":"1322_CR179","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/s41590-024-02047-w","volume":"26","author":"B Xiang","year":"2025","unstructured":"Xiang, B. et al. The epitranscriptional factor PCIF1 orchestrates CD8+ T cell ferroptosis and activation to control antitumor immunity. Nat. Immunol. 26, 252\u2013264 (2025).","journal-title":"Nat. Immunol."},{"key":"1322_CR180","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1038\/s41586-019-0985-x","volume":"567","author":"J Chen","year":"2019","unstructured":"Chen, J. et al. NR4A transcription factors limit CAR T cell function in solid tumours. Nature 567, 530\u2013534 (2019). This study identifies the NR4A family of\u00a0transcription factors as key drivers of T cell exhaustion, suggesting that their deletion could enhance efficacy in solid tumours.","journal-title":"Nature"},{"key":"1322_CR181","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1038\/s41586-024-07762-w","volume":"634","author":"Z Bai","year":"2024","unstructured":"Bai, Z. et al. Single-cell CAR T atlas reveals type 2 function in 8-year leukaemia remission. Nature 634, 702\u2013711 (2024).","journal-title":"Nature"},{"key":"1322_CR182","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1038\/s41587-023-02060-8","volume":"42","author":"Y Zhao","year":"2024","unstructured":"Zhao, Y. et al. IL-10-expressing CAR T cells resist dysfunction and mediate durable clearance of solid tumors and metastases. Nat. Biotechnol. 42, 1693\u20131704 (2024).","journal-title":"Nat. Biotechnol."},{"key":"1322_CR183","doi-asserted-by":"publisher","first-page":"eadj3020","DOI":"10.1126\/science.adj3020","volume":"387","author":"S Ma","year":"2025","unstructured":"Ma, S. et al. Nutrient-driven histone code determines exhausted CD8+ T cell fates. Science 387, eadj3020 (2025).","journal-title":"Science"},{"key":"1322_CR184","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1038\/s41586-019-1821-z","volume":"576","author":"J Wei","year":"2019","unstructured":"Wei, J. et al. Targeting REGNASE-1 programs long-lived effector T cells for cancer therapy. Nature 576, 471\u2013476 (2019). This study identifies regnase-1 as a crucial negative regulator of T cell function, showing that its ablation reprogrammes T cells into long-lived effector cells with enhanced antitumour efficacy.","journal-title":"Nature"},{"key":"1322_CR185","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.cmet.2022.02.009","volume":"34","author":"L Ye","year":"2022","unstructured":"Ye, L. et al. A genome-scale gain-of-function CRISPR screen in CD8 T cells identifies proline metabolism as a means to enhance CAR-T therapy. Cell Metab. 34, 595\u2013614.e14 (2022).","journal-title":"Cell Metab."},{"key":"1322_CR186","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1038\/s41586-022-05126-w","volume":"609","author":"J Carnevale","year":"2022","unstructured":"Carnevale, J. et al. RASA2 ablation in T cells boosts antigen sensitivity and long-term function. Nature 609, 174\u2013182 (2022). This work presents a systematic screen that discovers RASA2 as a checkpoint of TCR signalling, the ablation of which enhances CAR T cell persistence and function.","journal-title":"Nature"},{"key":"1322_CR187","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1038\/s41586-024-08071-y","volume":"635","author":"S-M Hwang","year":"2024","unstructured":"Hwang, S.-M. et al. Transgelin 2 guards T cell lipid metabolism and antitumour function. Nature 635, 1010\u20131018 (2024).","journal-title":"Nature"},{"key":"1322_CR188","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1038\/s41590-019-0480-4","volume":"20","author":"MW LaFleur","year":"2019","unstructured":"LaFleur, M. W. et al. PTPN2 regulates the generation of exhausted CD8+ T cell subpopulations and restrains tumor immunity. Nat. Immunol. 20, 1335\u20131347 (2019).","journal-title":"Nat. Immunol."},{"key":"1322_CR189","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1038\/s41590-024-01847-4","volume":"25","author":"P Guruprasad","year":"2024","unstructured":"Guruprasad, P. et al. The BTLA\u2013HVEM axis restricts CAR T cell efficacy in cancer. Nat. Immunol. 25, 1020\u20131032 (2024).","journal-title":"Nat. Immunol."},{"key":"1322_CR190","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-23331-5","volume":"12","author":"L Giuffrida","year":"2021","unstructured":"Giuffrida, L. et al. CRISPR\/Cas9 mediated deletion of the adenosine A2A receptor enhances CAR T cell efficacy. Nat. Commun. 12, 3236 (2021).","journal-title":"Nat. Commun."},{"key":"1322_CR191","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1038\/s41591-022-01726-1","volume":"28","author":"V Narayan","year":"2022","unstructured":"Narayan, V. et al. PSMA-targeting TGF\u03b2-insensitive armored CAR T\u2009cells in metastatic castration-resistant prostate cancer: a phase 1 trial. Nat. Med. 28, 724\u2013734 (2022).","journal-title":"Nat. Med."},{"key":"1322_CR192","doi-asserted-by":"publisher","first-page":"eadl4492","DOI":"10.1126\/science.adl4492","volume":"386","author":"TG Kang","year":"2024","unstructured":"Kang, T. G. et al. Epigenetic regulators of clonal hematopoiesis control CD8 T cell stemness during immunotherapy. Science 386, eadl4492 (2024).","journal-title":"Science"},{"key":"1322_CR193","doi-asserted-by":"publisher","first-page":"eabn5647","DOI":"10.1126\/science.abn5647","volume":"378","author":"KA Freitas","year":"2022","unstructured":"Freitas, K. A. et al. Enhanced T cell effector activity by targeting the Mediator kinase module. Science 378, eabn5647 (2022). This study identifies the Mediator kinase module (CDK8 and CDK19) as a transcriptional repressor of T cell effector function, demonstrating that its inhibition or deletion enhances the potency and persistence of antitumour T cells.","journal-title":"Science"},{"key":"1322_CR194","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1038\/s41586-022-04494-7","volume":"603","author":"M Legut","year":"2022","unstructured":"Legut, M. et al. A genome-scale screen for synthetic drivers of T cell proliferation. Nature 603, 728\u2013735 (2022).","journal-title":"Nature"},{"key":"1322_CR195","doi-asserted-by":"publisher","first-page":"6081","DOI":"10.1016\/j.cell.2021.11.016","volume":"184","author":"CR Good","year":"2021","unstructured":"Good, C. R. et al. An NK-like CAR T cell transition in CAR T cell dysfunction. Cell 184, 6081\u20136100.e26 (2021). This study redefines the understanding of CAR T cell dysfunction, showing that chronic antigen stimulation drives T cells to undergo a distinct form of transcriptional reprogramming towards a natural killer cell-like state characterized by the loss of T cell identity.","journal-title":"Cell"},{"key":"1322_CR196","doi-asserted-by":"publisher","DOI":"10.1172\/JCI169655","volume":"133","author":"P Zanvit","year":"2023","unstructured":"Zanvit, P. et al. Antitumor activity of AZD0754, a dnTGF\u03b2RII-armored, STEAP2-targeted CAR-T cell therapy, in prostate cancer. J. Clin. Invest. 133, e169655 (2023).","journal-title":"J. Clin. Invest."},{"key":"1322_CR197","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/s41586-018-0178-z","volume":"558","author":"JA Fraietta","year":"2018","unstructured":"Fraietta, J. A. et al. Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells. Nature 558, 307\u2013312 (2018).","journal-title":"Nature"},{"key":"1322_CR198","doi-asserted-by":"publisher","first-page":"eadn6509","DOI":"10.1126\/sciimmunol.adn6509","volume":"9","author":"RP Patel","year":"2024","unstructured":"Patel, R. P. et al. CD5 deletion enhances the antitumor activity of adoptive T cell therapies. Sci. Immunol. 9, eadn6509 (2024).","journal-title":"Sci. Immunol."},{"key":"1322_CR199","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1038\/s41586-022-04801-2","volume":"607","author":"A Kalbasi","year":"2022","unstructured":"Kalbasi, A. et al. Potentiating adoptive cell therapy using synthetic IL-9 receptors. Nature 607, 360\u2013365 (2022).","journal-title":"Nature"},{"key":"1322_CR200","doi-asserted-by":"publisher","first-page":"2388","DOI":"10.1016\/j.immuni.2023.09.001","volume":"56","author":"S Agarwal","year":"2023","unstructured":"Agarwal, S. et al. Deletion of the inhibitory co-receptor CTLA-4 enhances and invigorates chimeric antigen receptor T cells. Immunity 56, 2388\u20132407.e9 (2023).","journal-title":"Immunity"},{"key":"1322_CR201","doi-asserted-by":"publisher","first-page":"eaba7365","DOI":"10.1126\/science.aba7365","volume":"367","author":"EA Stadtmauer","year":"2020","unstructured":"Stadtmauer, E. A. et al. CRISPR-engineered T cells in patients with refractory cancer. Science 367, eaba7365 (2020). This landmark study reports the first-in-human phase I clinical trial of multiplex CRISPR\u2013Cas9 editing in patients with advanced cancer, demonstrating the safety and feasibility of precise genome engineering in adoptive cell therapy.","journal-title":"Science"},{"key":"1322_CR202","doi-asserted-by":"publisher","DOI":"10.1172\/JCI166028","volume":"133","author":"JE Jaspers","year":"2023","unstructured":"Jaspers, J. E. et al. IL-18\u2013secreting CAR T cells targeting DLL3 are highly effective in small cell lung cancer models. J. Clin. Invest. 133, e166028 (2023).","journal-title":"J. Clin. Invest."},{"key":"1322_CR203","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1016\/j.cell.2024.01.035","volume":"187","author":"V Tieu","year":"2024","unstructured":"Tieu, V. et al. A versatile CRISPR\u2013Cas13d platform for multiplexed transcriptomic regulation and metabolic engineering in primary human T cells. Cell 187, 1278\u20131295.e20 (2024). This study establishes a versatile CRISPR\u2013Cas13d platform for multiplexed transcriptomic engineering, enabling the precise modulation of T cell metabolism and function without the risk of permanent genomic alteration associated with DNA editing.","journal-title":"Cell"},{"key":"1322_CR204","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1038\/s41586-019-1325-x","volume":"571","author":"O Khan","year":"2019","unstructured":"Khan, O. et al. TOX transcriptionally and epigenetically programs CD8+ T cell exhaustion. Nature 571, 211\u2013218 (2019).","journal-title":"Nature"},{"key":"1322_CR205","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1038\/s41586-024-07018-7","volume":"626","author":"J Garcia","year":"2024","unstructured":"Garcia, J. et al. Naturally occurring T cell mutations enhance engineered T cell therapies. Nature 626, 626\u2013634 (2024). This study leverages the discovery of naturally occurring mutations in T cells of patients with T cell cancers to engineer CAR T cells with superior antitumour potency.","journal-title":"Nature"},{"key":"1322_CR206","doi-asserted-by":"publisher","first-page":"1982","DOI":"10.1158\/2159-8290.CD-22-1276","volume":"13","author":"MJ Dickinson","year":"2023","unstructured":"Dickinson, M. J. et al. A novel autologous CAR-T therapy, YTB323, with preserved T-cell stemness shows enhanced CAR T-cell efficacy in preclinical and early clinical development. Cancer Discov. 13, 1982\u20131997 (2023).","journal-title":"Cancer Discov."},{"key":"1322_CR207","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1016\/j.cmet.2024.12.007","volume":"37","author":"AT Frisch","year":"2025","unstructured":"Frisch, A. T. et al. Redirecting glucose flux during in vitro expansion generates epigenetically and metabolically superior T cells for cancer immunotherapy. Cell Metab. 37, 870\u2013885.e8 (2025).","journal-title":"Cell Metab."},{"key":"1322_CR208","doi-asserted-by":"publisher","first-page":"215710","DOI":"10.1016\/j.canlet.2022.215710","volume":"538","author":"L Shen","year":"2022","unstructured":"Shen, L. et al. Metabolic reprogramming by ex vivo glutamine inhibition endows CAR-T cells with less-differentiated phenotype and persistent antitumor activity. Cancer Lett. 538, 215710 (2022).","journal-title":"Cancer Lett."},{"key":"1322_CR209","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/j.cmet.2023.02.013","volume":"35","author":"CB Nava Lauson","year":"2023","unstructured":"Nava Lauson, C. B. et al. Linoleic acid potentiates CD8+ T cell metabolic fitness and antitumor immunity. Cell Metab. 35, 633\u2013650.e9 (2023).","journal-title":"Cell Metab."},{"key":"1322_CR210","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-24331-1","volume":"12","author":"M Luu","year":"2021","unstructured":"Luu, M. et al. Microbial short-chain fatty acids modulate CD8+ T cell responses and improve adoptive immunotherapy for cancer. Nat. Commun. 12, 4077 (2021).","journal-title":"Nat. Commun."},{"key":"1322_CR211","doi-asserted-by":"publisher","first-page":"3508","DOI":"10.1182\/blood-2009-09-241398","volume":"115","author":"JC Markley","year":"2010","unstructured":"Markley, J. C. & Sadelain, M. IL-7 and IL-21 are superior to IL-2 and IL-15 in promoting human T cell-mediated rejection of systemic lymphoma in immunodeficient mice. Blood 115, 3508\u20133519 (2010).","journal-title":"Blood"},{"key":"1322_CR212","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.immuni.2025.10.021","volume":"59","author":"S Castelli","year":"2026","unstructured":"Castelli, S. et al. IL-9 signaling redirects CAR T cell fate toward CD8+ memory and CD4+ cycling states, enhancing antitumor efficacy. Immunity 59, 195\u2013212.e11 (2026).","journal-title":"Immunity"},{"key":"1322_CR213","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1038\/nbt.4086","volume":"36","author":"K Adachi","year":"2018","unstructured":"Adachi, K. et al. IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor. Nat. Biotechnol. 36, 346\u2013351 (2018).","journal-title":"Nat. Biotechnol."},{"key":"1322_CR214","doi-asserted-by":"publisher","first-page":"4133","DOI":"10.1182\/blood-2011-12-400044","volume":"119","author":"HJ Pegram","year":"2012","unstructured":"Pegram, H. J. et al. Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning. Blood 119, 4133\u20134141 (2012).","journal-title":"Blood"},{"key":"1322_CR215","doi-asserted-by":"publisher","first-page":"2915","DOI":"10.1158\/1078-0432.CCR-18-1811","volume":"25","author":"Y Chen","year":"2019","unstructured":"Chen, Y. et al. Eradication of neuroblastoma by T cells redirected with an optimized GD2-specific chimeric antigen receptor and interleukin-15. Clin. Cancer Res. 25, 2915\u20132924 (2019).","journal-title":"Clin. Cancer Res."},{"key":"1322_CR216","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1038\/leu.2010.75","volume":"24","author":"V Hoyos","year":"2010","unstructured":"Hoyos, V. et al. Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma\/leukemia effects and safety. Leukemia 24, 1160\u20131170 (2010).","journal-title":"Leukemia"},{"key":"1322_CR217","doi-asserted-by":"publisher","first-page":"2130","DOI":"10.1016\/j.celrep.2018.04.051","volume":"23","author":"MP Avanzi","year":"2018","unstructured":"Avanzi, M. P. et al. Engineered tumor-targeted T cells mediate enhanced anti-tumor efficacy both directly and through activation of the endogenous immune system. Cell Rep. 23, 2130\u20132141 (2018).","journal-title":"Cell Rep."},{"key":"1322_CR218","doi-asserted-by":"publisher","first-page":"3205","DOI":"10.1016\/j.celrep.2017.11.063","volume":"21","author":"M Chmielewski","year":"2017","unstructured":"Chmielewski, M. & Abken, H. CAR T cells releasing IL-18 convert to T-BethighFoxO1low effectors that exhibit augmented activity against advanced solid tumors. Cell Rep. 21, 3205\u20133219 (2017).","journal-title":"Cell Rep."},{"key":"1322_CR219","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1158\/2326-6066.CIR-19-0293","volume":"8","author":"SA Batra","year":"2020","unstructured":"Batra, S. A. et al. Glypican-3-specific CAR T cells coexpressing IL15 and IL21 have superior expansion and antitumor activity against hepatocellular carcinoma. Cancer Immunol. Res. 8, 309\u2013320 (2020).","journal-title":"Cancer Immunol. Res."},{"key":"1322_CR220","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1038\/s41587-019-0398-2","volume":"38","author":"X Ma","year":"2020","unstructured":"Ma, X. et al. Interleukin-23 engineering improves CAR T cell function in solid tumors. Nat. Biotechnol. 38, 448\u2013459 (2020).","journal-title":"Nat. Biotechnol."},{"key":"1322_CR221","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1038\/s41375-020-0874-1","volume":"35","author":"X Li","year":"2021","unstructured":"Li, X., Daniyan, A. F., Lopez, A. V., Purdon, T. J. & Brentjens, R. J. Cytokine IL-36\u03b3 improves CAR T-cell functionality and induces endogenous antitumor response. Leukemia 35, 506\u2013521 (2021).","journal-title":"Leukemia"},{"key":"1322_CR222","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1038\/s41590-020-0676-7","volume":"21","author":"J Lai","year":"2020","unstructured":"Lai, J. et al. Adoptive cellular therapy with T cells expressing the dendritic cell growth factor Flt3L drives epitope spreading and antitumor immunity. Nat. Immunol. 21, 914\u2013926 (2020).","journal-title":"Nat. Immunol."},{"key":"1322_CR223","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41421-023-00625-0","volume":"10","author":"W Lei","year":"2024","unstructured":"Lei, W. et al. Safety and feasibility of anti-CD19 CAR T cells expressing inducible IL-7 and CCL19 in patients with relapsed or refractory large B-cell lymphoma. Cell Discov. 10, 5 (2024).","journal-title":"Cell Discov."},{"key":"1322_CR224","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1056\/NEJMoa2408771","volume":"392","author":"J Svoboda","year":"2025","unstructured":"Svoboda, J. et al. Enhanced CAR T-cell therapy for lymphoma after previous failure. N. Engl. J. Med. 392, 1824\u20131835 (2025). This pivotal trial shows that an IL-18-armoured, CD19-targeted CAR T cell product can successfully induce remission in patients with lymphoma who have failed prior CAR T cell treatment, addressing a crucial unmet need in the management of therapy-resistant disease.","journal-title":"N. Engl. J. Med."},{"key":"1322_CR225","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1038\/s41570-025-00768-6","volume":"9","author":"EL Adams","year":"2025","unstructured":"Adams, E. L. et al. Small-molecule control of CAR T cells. Nat. Rev. Chem. 9, 809\u2013825 (2025).","journal-title":"Nat. Rev. Chem."},{"key":"1322_CR226","doi-asserted-by":"publisher","first-page":"103941","DOI":"10.1016\/j.ebiom.2022.103941","volume":"77","author":"D Gumber","year":"2022","unstructured":"Gumber, D. & Wang, L. D. Improving CAR-T immunotherapy: overcoming the challenges of T cell exhaustion. EBioMedicine 77, 103941 (2022).","journal-title":"EBioMedicine"},{"key":"1322_CR227","doi-asserted-by":"publisher","first-page":"eaba1786","DOI":"10.1126\/science.aba1786","volume":"372","author":"EW Weber","year":"2021","unstructured":"Weber, E. W. et al. Transient rest restores functionality in exhausted CAR-T cells through epigenetic remodeling. Science 372, eaba1786 (2021). This study challenges the dogma that T cell exhaustion is permanent, demonstrating that transiently inhibiting CAR signalling induces epigenetic remodelling and restores the functional potency of exhausted CAR T cells.","journal-title":"Science"},{"key":"1322_CR228","doi-asserted-by":"publisher","first-page":"233","DOI":"10.3389\/fcell.2019.00233","volume":"7","author":"R-Y Zhang","year":"2019","unstructured":"Zhang, R.-Y. et al. Doxycycline inducible chimeric antigen receptor T cells targeting CD147 for hepatocellular carcinoma therapy. Front. Cell Dev. Biol. 7, 233 (2019).","journal-title":"Front. Cell Dev. Biol."},{"key":"1322_CR229","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0197349","volume":"13","author":"E Drent","year":"2018","unstructured":"Drent, E. et al. Feasibility of controlling CD38-CAR T cell activity with a Tet-on inducible CAR design. PLoS ONE 13, e0197349 (2018).","journal-title":"PLoS ONE"},{"key":"1322_CR230","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/s42003-021-01664-7","volume":"4","author":"Y Greenshpan","year":"2021","unstructured":"Greenshpan, Y. et al. Synthetic promoters to induce immune-effectors into the tumor microenvironment. Commun. Biol. 4, 143 (2021).","journal-title":"Commun. Biol."},{"key":"1322_CR231","doi-asserted-by":"publisher","first-page":"2691","DOI":"10.1016\/j.ymthe.2021.05.006","volume":"29","author":"B Webster","year":"2021","unstructured":"Webster, B. et al. Self-driving armored CAR-T cells overcome a suppressive milieu and eradicate CD19+ Raji lymphoma in preclinical models. Mol. Ther. 29, 2691\u20132706 (2021).","journal-title":"Mol. Ther."},{"key":"1322_CR232","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/nature21405","volume":"543","author":"J Eyquem","year":"2017","unstructured":"Eyquem, J. et al. Targeting a CAR to the TRAC locus with CRISPR\/Cas9 enhances tumour rejection. Nature 543, 113\u2013117 (2017). This study establishes that placing the CAR gene under the control of the endogenous TCR promoter (through TRAC integration) prevents tonic signalling and exhaustion.","journal-title":"Nature"},{"key":"1322_CR233","doi-asserted-by":"publisher","first-page":"E10898","DOI":"10.1073\/pnas.1810060115","volume":"115","author":"S Viaud","year":"2018","unstructured":"Viaud, S. et al. Switchable control over in vivo CAR T expansion, B cell depletion, and induction of memory. Proc. Natl Acad. Sci. USA 115, E10898\u2013E10906 (2018).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1322_CR234","doi-asserted-by":"publisher","first-page":"aab4077","DOI":"10.1126\/science.aab4077","volume":"350","author":"C-Y Wu","year":"2015","unstructured":"Wu, C.-Y., Roybal, K. T., Puchner, E. M., Onuffer, J. & Lim, W. A. Remote control of therapeutic T cells through a small molecule-gated chimeric receptor. Science 350, aab4077 (2015).","journal-title":"Science"},{"key":"1322_CR235","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-11869-4","volume":"10","author":"L Jin","year":"2019","unstructured":"Jin, L. et al. CXCR1- or CXCR2-modified CAR T cells co-opt IL-8 for maximal antitumor efficacy in solid tumors. Nat. Commun. 10, 4016 (2019).","journal-title":"Nat. Commun."},{"key":"1322_CR236","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1097\/CJI.0b013e3181ee6675","volume":"33","author":"JA Craddock","year":"2010","unstructured":"Craddock, J. A. et al. Enhanced tumor trafficking of GD2 chimeric antigen receptor T cells by expression of the chemokine receptor CCR2b. J. Immunother. 33, 780\u2013788 (2010).","journal-title":"J. Immunother."},{"key":"1322_CR237","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s40425-016-0125-1","volume":"4","author":"I Siddiqui","year":"2016","unstructured":"Siddiqui, I., Erreni, M., van Brakel, M., Debets, R. & Allavena, P. Enhanced recruitment of genetically modified CX3CR1-positive human T cells into Fractalkine\/CX3CL1 expressing tumors: importance of the chemokine gradient. J. Immunother. Cancer 4, 21 (2016).","journal-title":"J. Immunother. Cancer"},{"key":"1322_CR238","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1038\/s41551-021-00737-6","volume":"5","author":"S Lesch","year":"2021","unstructured":"Lesch, S. et al. T cells armed with C-X-C chemokine receptor type 6 enhance adoptive cell therapy for pancreatic tumours. Nat. Biomed. Eng. 5, 1246\u20131260 (2021).","journal-title":"Nat. Biomed. Eng."},{"key":"1322_CR239","doi-asserted-by":"publisher","first-page":"eadl6432","DOI":"10.1126\/scitranslmed.adl6432","volume":"17","author":"H Wang","year":"2025","unstructured":"Wang, H. et al. Triple knockdown of CD11a, CD49d, and PSGL1 in T cells reduces CAR-T cell toxicity but preserves activity against solid tumors in mice. Sci. Transl. Med. 17, eadl6432 (2025).","journal-title":"Sci. Transl. Med."},{"key":"1322_CR240","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/s43018-020-00147-8","volume":"2","author":"W Ma","year":"2020","unstructured":"Ma, W. et al. Targeting PAK4 to reprogram the vascular microenvironment and improve CAR-T immunotherapy for glioblastoma. Nat. Cancer 2, 83\u201397 (2020).","journal-title":"Nat. Cancer"},{"key":"1322_CR241","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005583","volume":"11","author":"X Dong","year":"2023","unstructured":"Dong, X. et al. Anti-VEGF therapy improves EGFR-vIII\u2013CAR-T cell delivery and efficacy in syngeneic glioblastoma models in mice. J. Immunother. Cancer 11, e005583 (2023).","journal-title":"J. Immunother. Cancer"},{"key":"1322_CR242","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1038\/nm.3833","volume":"21","author":"I Caruana","year":"2015","unstructured":"Caruana, I. et al. Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T lymphocytes. Nat. Med. 21, 524\u2013529 (2015).","journal-title":"Nat. Med."},{"key":"1322_CR243","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1158\/2326-6066.CIR-13-0027","volume":"2","author":"L-CS Wang","year":"2014","unstructured":"Wang, L.-C. S. et al. Targeting fibroblast activation protein in tumor stroma with chimeric antigen receptor T cells can inhibit tumor growth and augment host immunity without severe toxicity. Cancer Immunol. Res. 2, 154\u2013166 (2014).","journal-title":"Cancer Immunol. Res."},{"key":"1322_CR244","doi-asserted-by":"publisher","first-page":"101053","DOI":"10.1016\/j.xcrm.2023.101053","volume":"4","author":"I-Y Jung","year":"2023","unstructured":"Jung, I.-Y. et al. Tissue-resident memory CAR T cells with stem-like characteristics display enhanced efficacy against solid and liquid tumors. Cell Rep. Med. 4, 101053 (2023).","journal-title":"Cell Rep. Med."},{"key":"1322_CR245","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1038\/s43018-025-00905-6","volume":"6","author":"H Ni","year":"2025","unstructured":"Ni, H. et al. FLASH radiation reprograms lipid metabolism and macrophage immunity and sensitizes medulloblastoma to CAR-T cell therapy. Nat. Cancer 6, 460\u2013473 (2025).","journal-title":"Nat. Cancer"},{"key":"1322_CR246","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1158\/2159-8290.CD-23-0101","volume":"13","author":"M Hamieh","year":"2023","unstructured":"Hamieh, M., Mansilla-Soto, J., Rivi\u00e8re, I. & Sadelain, M. Programming CAR T cell tumor recognition: tuned antigen sensing and logic gating. Cancer Discov. 13, 829\u2013843 (2023).","journal-title":"Cancer Discov."},{"key":"1322_CR247","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1182\/blood.2019000050","volume":"134","author":"MJ Pont","year":"2019","unstructured":"Pont, M. J. et al. \u03b3-Secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma. Blood 134, 1585\u20131597 (2019).","journal-title":"Blood"},{"key":"1322_CR248","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/j.ccell.2022.04.001","volume":"40","author":"MB Leick","year":"2022","unstructured":"Leick, M. B. et al. Non-cleavable hinge enhances avidity and expansion of CAR-T cells for acute myeloid leukemia. Cancer Cell 40, 494\u2013508.e5 (2022).","journal-title":"Cancer Cell"},{"key":"1322_CR249","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-26683-0","volume":"12","author":"N El Khawanky","year":"2021","unstructured":"El Khawanky, N. et al. Demethylating therapy increases anti-CD123 CAR T cell cytotoxicity against acute myeloid leukemia. Nat. Commun. 12, 6436 (2021).","journal-title":"Nat. Commun."},{"key":"1322_CR250","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.ccell.2024.11.006","volume":"43","author":"Y Isshiki","year":"2025","unstructured":"Isshiki, Y. et al. EZH2 inhibition enhances T cell immunotherapies by inducing lymphoma immunogenicity and improving T cell function. Cancer Cell 43, 49\u201368.e9 (2025).","journal-title":"Cancer Cell"},{"key":"1322_CR251","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1001\/jamaoncol.2021.0168","volume":"7","author":"F Hauth","year":"2021","unstructured":"Hauth, F., Ho, A. Y., Ferrone, S. & Duda, D. G. Radiotherapy to enhance chimeric antigen receptor T-cell therapeutic efficacy in solid tumors: a narrative review. JAMA Oncol. 7, 1051 (2021).","journal-title":"JAMA Oncol."},{"key":"1322_CR252","doi-asserted-by":"publisher","first-page":"1455163","DOI":"10.3389\/fimmu.2024.1455163","volume":"15","author":"E Ponterio","year":"2024","unstructured":"Ponterio, E., Haas, T. L. & De Maria, R. Oncolytic virus and CAR-T cell therapy in solid tumors. Front. Immunol. 15, 1455163 (2024).","journal-title":"Front. Immunol."},{"key":"1322_CR253","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1158\/2159-8290.CD-19-0945","volume":"10","author":"RG Majzner","year":"2020","unstructured":"Majzner, R. G. et al. Tuning the antigen density requirement for CAR T-cell activity. Cancer Discov. 10, 702\u2013723 (2020).","journal-title":"Cancer Discov."},{"key":"1322_CR254","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1016\/j.ccell.2025.02.008","volume":"43","author":"C Pham-Danis","year":"2025","unstructured":"Pham-Danis, C. et al. Restoration of LAT activity improves CAR T cell sensitivity and persistence in response to antigen-low acute lymphoblastic leukemia. Cancer Cell 43, 482\u2013502.e9 (2025).","journal-title":"Cancer Cell"},{"key":"1322_CR255","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.1038\/s43018-025-01056-4","volume":"6","author":"MC Rotiroti","year":"2025","unstructured":"Rotiroti, M. C. et al. Engineering T cells with a membrane-tethered version of SLP-76 overcomes antigen-low resistance to CAR T cell therapy. Nat. Cancer 6, 1940\u20131954 (2025).","journal-title":"Nat. Cancer"},{"key":"1322_CR256","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-009013","volume":"12","author":"R Freeman","year":"2024","unstructured":"Freeman, R. et al. Developing a membrane-proximal CD33-targeting CAR T cell. J. Immunother. Cancer 12, e009013 (2024).","journal-title":"J. Immunother. Cancer"},{"key":"1322_CR257","doi-asserted-by":"publisher","first-page":"eabb5191","DOI":"10.1126\/scitranslmed.abb5191","volume":"13","author":"Y Liu","year":"2021","unstructured":"Liu, Y. et al. Chimeric STAR receptors using TCR machinery mediate robust responses against solid tumors. Sci. Transl. Med. 13, eabb5191 (2021).","journal-title":"Sci. Transl. Med."},{"key":"1322_CR258","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1126\/science.adv7378","volume":"391","author":"SA Hanina","year":"2026","unstructured":"Hanina, S. A. et al. Sensitive CAR T cells redefine targetable CD70 expression in solid tumors. Science 391, 896\u2013905 (2026).","journal-title":"Science"},{"key":"1322_CR259","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/s41591-021-01621-1","volume":"28","author":"J Mansilla-Soto","year":"2022","unstructured":"Mansilla-Soto, J. et al. HLA-independent T cell receptors for targeting tumors with low antigen density. Nat. Med. 28, 345\u2013352 (2022).","journal-title":"Nat. Med."},{"key":"1322_CR260","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-10097-0","volume":"10","author":"PA Baeuerle","year":"2019","unstructured":"Baeuerle, P. A. et al. Synthetic TRuC receptors engaging the complete T cell receptor for potent anti-tumor response. Nat. Commun. 10, 2087 (2019).","journal-title":"Nat. Commun."},{"key":"1322_CR261","doi-asserted-by":"publisher","first-page":"2182058","DOI":"10.1080\/2162402X.2023.2182058","volume":"12","author":"J Ding","year":"2023","unstructured":"Ding, J. et al. Mesothelin-targeting T cells bearing a novel T cell receptor fusion construct (TRuC) exhibit potent antitumor efficacy against solid tumors. Oncoimmunology 12, 2182058 (2023).","journal-title":"Oncoimmunology"},{"key":"1322_CR262","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1038\/s41375-024-02351-2","volume":"38","author":"D Atar","year":"2024","unstructured":"Atar, D. et al. Rational combinatorial targeting by adapter CAR-T-cells (AdCAR-T) prevents antigen escape in acute myeloid leukemia. Leukemia 38, 2183\u20132195 (2024).","journal-title":"Leukemia"},{"key":"1322_CR263","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1038\/s41375-023-01905-0","volume":"37","author":"D Nixdorf","year":"2023","unstructured":"Nixdorf, D. et al. Adapter CAR T cells to counteract T-cell exhaustion and enable flexible targeting in AML. Leukemia 37, 1298\u20131310 (2023).","journal-title":"Leukemia"},{"key":"1322_CR264","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1038\/s41591-020-1081-3","volume":"26","author":"NN Shah","year":"2020","unstructured":"Shah, N. N. et al. Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial. Nat. Med. 26, 1569\u20131575 (2020).","journal-title":"Nat. Med."},{"key":"1322_CR265","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1038\/s43018-021-00244-2","volume":"2","author":"K Hirabayashi","year":"2021","unstructured":"Hirabayashi, K. et al. Dual targeting CAR-T cells with optimal costimulation and metabolic fitness enhance antitumor activity and prevent escape in solid tumors. Nat. Cancer 2, 904\u2013918 (2021).","journal-title":"Nat. Cancer"},{"key":"1322_CR266","doi-asserted-by":"publisher","first-page":"eabc6401","DOI":"10.1126\/scitranslmed.abc6401","volume":"13","author":"D Schneider","year":"2021","unstructured":"Schneider, D. et al. Trispecific CD19\u2013CD20\u2013CD22-targeting duoCAR-T cells eliminate antigen-heterogeneous B cell tumors in preclinical models. Sci. Transl. Med. 13, eabc6401 (2021).","journal-title":"Sci. Transl. Med."},{"key":"1322_CR267","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1016\/S1470-2045(23)00436-9","volume":"24","author":"J Pan","year":"2023","unstructured":"Pan, J. et al. Sequential CD19 and CD22 chimeric antigen receptor T-cell therapy for childhood refractory or relapsed B-cell acute lymphocytic leukaemia: a single-arm, phase 2 study. Lancet Oncol. 24, 1229\u20131241 (2023).","journal-title":"Lancet Oncol."},{"key":"1322_CR268","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1038\/s41587-022-01650-2","volume":"41","author":"PJ Chockley","year":"2023","unstructured":"Chockley, P. J., Ibanez-Vega, J., Krenciute, G., Talbot, L. J. & Gottschalk, S. Synapse-tuned CARs enhance immune cell anti-tumor activity. Nat. Biotechnol. 41, 1434\u20131445 (2023).","journal-title":"Nat. Biotechnol."},{"key":"1322_CR269","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1158\/0008-5472.CAN-23-1038","volume":"84","author":"X Zhu","year":"2024","unstructured":"Zhu, X. et al. Hypoxia-responsive CAR-T cells exhibit reduced exhaustion and enhanced efficacy in solid tumors. Cancer Res. 84, 84\u2013100 (2024).","journal-title":"Cancer Res."},{"key":"1322_CR270","doi-asserted-by":"publisher","first-page":"100227","DOI":"10.1016\/j.xcrm.2021.100227","volume":"2","author":"P Kosti","year":"2021","unstructured":"Kosti, P. et al. Hypoxia-sensing CAR T cells provide safety and efficacy in treating solid tumors. Cell Rep. Med. 2, 100227 (2021).","journal-title":"Cell Rep. Med."},{"key":"1322_CR271","doi-asserted-by":"publisher","first-page":"3514","DOI":"10.1200\/JCO.2024.42.16_suppl.3514","volume":"42","author":"H Zhang","year":"2024","unstructured":"Zhang, H. et al. Phase I trial of hypoxia-responsive CEA CAR-T cell therapy in patients with heavily pretreated solid tumor via intraperitoneal or intravenous transfusion. J. Clin. Oncol. 42, 3514\u20133514 (2024).","journal-title":"J. Clin. Oncol."},{"key":"1322_CR272","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-006522","volume":"11","author":"K Lontos","year":"2023","unstructured":"Lontos, K. et al. Metabolic reprogramming via an engineered PGC-1\u03b1 improves human chimeric antigen receptor T-cell therapy against solid tumors. J. Immunother. Cancer 11, e006522 (2023).","journal-title":"J. Immunother. Cancer"},{"key":"1322_CR273","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-52666-y","volume":"15","author":"JA Guerrero","year":"2024","unstructured":"Guerrero, J. A. et al. GLUT1 overexpression in CAR-T cells induces metabolic reprogramming and enhances potency. Nat. Commun. 15, 8658 (2024).","journal-title":"Nat. Commun."},{"key":"1322_CR274","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.177141","volume":"9","author":"R Hatae","year":"2024","unstructured":"Hatae, R. et al. Enhancing CAR-T cell metabolism to overcome hypoxic conditions in the brain tumor microenvironment. JCI Insight 9, e177141 (2024).","journal-title":"JCI Insight"},{"key":"1322_CR275","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20200844","volume":"218","author":"N Xu","year":"2021","unstructured":"Xu, N. et al. STING agonist promotes CAR T cell trafficking and persistence in breast cancer. J. Exp. Med. 218, e20200844 (2021).","journal-title":"J. Exp. Med."},{"key":"1322_CR276","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003351","volume":"9","author":"E Conde","year":"2021","unstructured":"Conde, E. et al. Epitope spreading driven by the joint action of CART cells and pharmacological STING stimulation counteracts tumor escape via antigen-loss variants. J. Immunother. Cancer 9, e003351 (2021).","journal-title":"J. Immunother. Cancer"},{"key":"1322_CR277","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1016\/j.ccell.2024.07.002","volume":"42","author":"U Uslu","year":"2024","unstructured":"Uslu, U., Castelli, S. & June, C. H. CAR T cell combination therapies to treat cancer. Cancer Cell 42, 1319\u20131325 (2024).","journal-title":"Cancer Cell"},{"key":"1322_CR278","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/s41586-024-07443-8","volume":"630","author":"SA Yamada-Hunter","year":"2024","unstructured":"Yamada-Hunter, S. A. et al. Engineered CD47 protects T cells for enhanced antitumour immunity. Nature 630, 457\u2013465 (2024).","journal-title":"Nature"},{"key":"1322_CR279","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1038\/s41591-022-01702-9","volume":"28","author":"M Smith","year":"2022","unstructured":"Smith, M. et al. Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy. Nat. Med. 28, 713\u2013723 (2022).","journal-title":"Nat. Med."},{"key":"1322_CR280","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1038\/s41591-023-02234-6","volume":"29","author":"CK Stein-Thoeringer","year":"2023","unstructured":"Stein-Thoeringer, C. K. et al. A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapy. Nat. Med. 29, 906\u2013916 (2023).","journal-title":"Nat. Med."},{"key":"1322_CR281","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/s41571-024-00903-0","volume":"21","author":"JN Brudno","year":"2024","unstructured":"Brudno, J. N. & Kochenderfer, J. N. Current understanding and management of CAR T cell-associated toxicities. Nat. Rev. Clin. Oncol. 21, 501\u2013521 (2024).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1322_CR282","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1158\/2326-6066.CIR-16-0043","volume":"4","author":"R Sakemura","year":"2016","unstructured":"Sakemura, R. et al. A Tet-On inducible system for controlling CD19-chimeric antigen receptor expression upon drug administration. Cancer Immunol. Res. 4, 658\u2013668 (2016).","journal-title":"Cancer Immunol. Res."},{"key":"1322_CR283","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1158\/2326-6066.CIR-13-0008","volume":"1","author":"E Lanitis","year":"2013","unstructured":"Lanitis, E. et al. Chimeric antigen receptor T cells with dissociated signaling domains exhibit focused antitumor activity with reduced potential for toxicity in vivo. Cancer Immunol. Res. 1, 43\u201353 (2013).","journal-title":"Cancer Immunol. Res."},{"key":"1322_CR284","doi-asserted-by":"publisher","first-page":"eabb6295","DOI":"10.1126\/scitranslmed.abb6295","volume":"13","author":"M Jan","year":"2021","unstructured":"Jan, M. et al. Reversible ON- and OFF-switch chimeric antigen receptors controlled by lenalidomide. Sci. Transl. Med. 13, eabb6295 (2021).","journal-title":"Sci. Transl. Med."},{"key":"1322_CR285","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1016\/j.cell.2022.03.041","volume":"185","author":"L Labanieh","year":"2022","unstructured":"Labanieh, L. et al. Enhanced safety and efficacy of protease-regulated CAR-T cell receptors. Cell 185, 1745\u20131763.e22 (2022). This study introduces the SNIP system, a novel platform that uses FDA-approved protease inhibitors to tune CAR protein levels, enabling precise, reversible control of T cell activity to prevent exhaustion and minimize toxicity.","journal-title":"Cell"},{"key":"1322_CR286","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1016\/j.ccell.2022.08.008","volume":"40","author":"H-S Li","year":"2022","unstructured":"Li, H.-S. et al. High-performance multiplex drug-gated CAR circuits. Cancer Cell 40, 1294\u20131305.e4 (2022).","journal-title":"Cancer Cell"},{"key":"1322_CR287","doi-asserted-by":"publisher","first-page":"eadl4237","DOI":"10.1126\/science.adl4237","volume":"386","author":"MS Simic","year":"2024","unstructured":"Simic, M. S. et al. Programming tissue-sensing T cells that deliver therapies to the brain. Science 386, eadl4237 (2024).","journal-title":"Science"},{"key":"1322_CR288","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1016\/j.cell.2016.01.011","volume":"164","author":"KT Roybal","year":"2016","unstructured":"Roybal, K. T. et al. Precision tumor recognition by T cells with combinatorial antigen-sensing circuits. Cell 164, 770\u2013779 (2016). This work introduces synNotch receptors, enabling \u2018logic gated\u2019 circuits that enable T cells to sense multiple antigens and spatially restrict their activity to the tumour.","journal-title":"Cell"},{"key":"1322_CR289","doi-asserted-by":"publisher","first-page":"4247","DOI":"10.1182\/blood-2004-11-4564","volume":"105","author":"KC Straathof","year":"2005","unstructured":"Straathof, K. C. et al. An inducible caspase 9 safety switch for T-cell therapy. Blood 105, 4247\u20134254 (2005).","journal-title":"Blood"},{"key":"1322_CR290","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1089\/hum.1995.6.6-813","volume":"6","author":"C Bordignon","year":"1995","unstructured":"Bordignon, C. et al. Transfer of the HSV-tk gene into donor peripheral blood lymphocytes for in vivo modulation of donor anti-tumor immunity after allogeneic bone marrow transplantation. Hum. Gene Ther. 6, 813\u2013819 (1995).","journal-title":"Hum. Gene Ther."},{"key":"1322_CR291","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1038\/leu.2016.35","volume":"30","author":"RC Lynn","year":"2016","unstructured":"Lynn, R. C. et al. High-affinity FR\u03b2-specific CAR T cells eradicate AML and normal myeloid lineage without HSC toxicity. Leukemia 30, 1355\u20131364 (2016).","journal-title":"Leukemia"},{"key":"1322_CR292","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1038\/s41586-023-05778-2","volume":"615","author":"AM Tousley","year":"2023","unstructured":"Tousley, A. M. et al. Co-opting signalling molecules enables logic-gated control of CAR T cells. Nature 615, 507\u2013516 (2023). This study introduces a novel logic-gated strategy that co-opts the native proximal signalling machinery of T cells (such as LAT and SLP76) to create strict \u2018AND\u2019 gates, enabling precise discrimination between dual antigen-positive tumours and single antigen-positive normal tissues.","journal-title":"Nature"},{"key":"1322_CR293","doi-asserted-by":"publisher","first-page":"215ra172","DOI":"10.1126\/scitranslmed.3006597","volume":"5","author":"VD Fedorov","year":"2013","unstructured":"Fedorov, V. D., Themeli, M. & Sadelain, M. PD-1- and CTLA-4-based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses. Sci. Transl. Med. 5, 215ra172 (2013).","journal-title":"Sci. Transl. Med."},{"key":"1322_CR294","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1126\/science.abc1855","volume":"371","author":"RA Hernandez-Lopez","year":"2021","unstructured":"Hernandez-Lopez, R. A. et al. T cell circuits that sense antigen density with an ultrasensitive threshold. Science 371, 1166\u20131171 (2021).","journal-title":"Science"},{"key":"1322_CR295","doi-asserted-by":"publisher","first-page":"3505","DOI":"10.1158\/0008-5472.CAN-15-0139","volume":"75","author":"HG Caruso","year":"2015","unstructured":"Caruso, H. G. et al. Tuning sensitivity of CAR to EGFR density limits recognition of normal tissue while maintaining potent antitumor activity. Cancer Res. 75, 3505\u20133518 (2015).","journal-title":"Cancer Res."},{"key":"1322_CR296","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s12929-021-00709-7","volume":"28","author":"T Klaus","year":"2021","unstructured":"Klaus, T. & Deshmukh, S. pH-responsive antibodies for therapeutic applications. J. Biomed. Sci. 28, 11 (2021).","journal-title":"J. Biomed. Sci."},{"key":"1322_CR297","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1126\/science.aar3246","volume":"359","author":"JT Sockolosky","year":"2018","unstructured":"Sockolosky, J. T. et al. Selective targeting of engineered T cells using orthogonal IL-2 cytokine\u2013receptor complexes. Science 359, 1037\u20131042 (2018). This study pioneers the use of orthogonal cytokine\u2013receptor pairs, showing that engineering T cells to respond exclusively to a mutant form of IL-2 allows for their selective proliferation and modulation without activating the endogenous immune system.","journal-title":"Science"},{"key":"1322_CR298","doi-asserted-by":"publisher","first-page":"eaba1624","DOI":"10.1126\/science.aba1624","volume":"378","author":"GM Allen","year":"2022","unstructured":"Allen, G. M. et al. Synthetic cytokine circuits that drive T cells into immune-excluded tumors. Science 378, eaba1624 (2022). This study engineers T cells with synthetic gene circuits that trigger the local production of IL-2 only upon tumour recognition, enabling them to overcome immune exclusion and infiltrate solid tumours while avoiding systemic toxicity.","journal-title":"Science"},{"key":"1322_CR299","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1038\/s41551-023-01143-w","volume":"8","author":"M Bell","year":"2024","unstructured":"Bell, M. et al. Modular chimeric cytokine receptors with leucine zippers enhance the antitumour activity of CAR T cells via JAK\/STAT signalling. Nat. Biomed. Eng. 8, 380\u2013396 (2024).","journal-title":"Nat. Biomed. Eng."},{"key":"1322_CR300","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1038\/s41551-025-01509-2","volume":"10","author":"JP Murad","year":"2026","unstructured":"Murad, J. P. et al. Solid tumour CAR-T cells engineered with fusion proteins targeting PD-L1 for localized IL-12 delivery. Nat. Biomed. Eng.\u00a010, 613\u2013629 (2026).","journal-title":"Nat. Biomed. Eng."},{"key":"1322_CR301","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1038\/s41586-025-09212-7","volume":"644","author":"AXY Chen","year":"2025","unstructured":"Chen, A. X. Y. et al. Rewiring endogenous genes in CAR T cells for tumour-restricted payload delivery. Nature 644, 241\u2013251 (2025). This work presents an innovative synthetic biology approach that repurposes endogenous gene regulation to drive the tumour-specific release of therapeutic payloads.","journal-title":"Nature"},{"key":"1322_CR302","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1182\/blood.2021010858","volume":"138","author":"KP Micklethwaite","year":"2021","unstructured":"Micklethwaite, K. P. et al. Investigation of product-derived lymphoma following infusion of piggyBac -modified CD19 chimeric antigen receptor T cells. Blood 138, 1391\u20131405 (2021).","journal-title":"Blood"},{"key":"1322_CR303","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1182\/blood.2024024166","volume":"143","author":"M Elsallab","year":"2024","unstructured":"Elsallab, M. et al. Second primary malignancies after commercial CAR T-cell therapy: analysis of the FDA adverse events reporting system. Blood 143, 2099\u20132105 (2024).","journal-title":"Blood"},{"key":"1322_CR304","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1038\/s41375-025-02574-x","volume":"39","author":"T Braun","year":"2025","unstructured":"Braun, T., Kuschel, F., Reiche, K., Merz, M. & Herling, M. Emerging T-cell lymphomas after CAR T-cell therapy. Leukemia 39, 1337\u20131341 (2025).","journal-title":"Leukemia"},{"key":"1322_CR305","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1056\/NEJMp2400209","volume":"390","author":"N Verdun","year":"2024","unstructured":"Verdun, N. & Marks, P. Secondary cancers after chimeric antigen receptor T-cell therapy. N. Engl. J. Med. 390, 584\u2013586 (2024).","journal-title":"N. Engl. J. Med."},{"key":"1322_CR306","doi-asserted-by":"publisher","first-page":"2132","DOI":"10.1038\/s41591-025-03813-5","volume":"31","author":"K Rejeski","year":"2025","unstructured":"Rejeski, K., Hill, J. A., Dahiya, S. & Jain, M. D. Noncanonical and mortality-defining toxicities of CAR T cell therapy. Nat. Med. 31, 2132\u20132146 (2025).","journal-title":"Nat. Med."},{"key":"1322_CR307","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1016\/j.ymthe.2025.03.005","volume":"33","author":"KK Patel","year":"2025","unstructured":"Patel, K. K., Tariveranmoshabad, M., Kadu, S., Shobaki, N. & June, C. From concept to cure: the evolution of CAR-T cell therapy. Mol. Ther. 33, 2123\u20132140 (2025).","journal-title":"Mol. Ther."},{"key":"1322_CR308","doi-asserted-by":"publisher","first-page":"4826","DOI":"10.1016\/j.cell.2024.07.056","volume":"187","author":"DJ Baker","year":"2024","unstructured":"Baker, D. J. & June, C. H. Off-the-shelf CAR-T cells could prove paradigm shifting for autoimmune diseases. Cell 187, 4826\u20134828 (2024).","journal-title":"Cell"},{"key":"1322_CR309","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s40164-025-00654-3","volume":"14","author":"Z Lyu","year":"2025","unstructured":"Lyu, Z. et al. Addressing graft-versus-host disease in allogeneic cell-based immunotherapy for cancer. Exp. Hematol. Oncol. 14, 66 (2025).","journal-title":"Exp. Hematol. Oncol."},{"key":"1322_CR310","doi-asserted-by":"publisher","first-page":"5697","DOI":"10.1182\/blood-2012-01-405365","volume":"119","author":"H Torikai","year":"2012","unstructured":"Torikai, H. et al. A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR. Blood 119, 5697\u20135705 (2012).","journal-title":"Blood"},{"key":"1322_CR311","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1158\/2326-6066.CIR-18-0508","volume":"8","author":"Y Kagoya","year":"2020","unstructured":"Kagoya, Y. et al. Genetic ablation of HLA class I, class II, and the T-cell receptor enables allogeneic T cells to be used for adoptive T-cell therapy. Cancer Immunol. Res. 8, 926\u2013936 (2020).","journal-title":"Cancer Immunol. Res."},{"key":"1322_CR312","doi-asserted-by":"publisher","first-page":"2695","DOI":"10.1182\/bloodadvances.2021006232","volume":"6","author":"Y Guo","year":"2022","unstructured":"Guo, Y. et al. CRISPR\/Cas9 genome-edited universal CAR T cells in patients with relapsed\/refractory lymphoma. Blood Adv. 6, 2695\u20132699 (2022).","journal-title":"Blood Adv."},{"key":"1322_CR313","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1182\/blood-2013-03-478255","volume":"122","author":"H Torikai","year":"2013","unstructured":"Torikai, H. et al. Toward eliminating HLA class I expression to generate universal cells from allogeneic donors. Blood 122, 1341\u20131349 (2013).","journal-title":"Blood"},{"key":"1322_CR314","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/j.trecan.2025.03.001","volume":"11","author":"Y-R Li","year":"2025","unstructured":"Li, Y.-R., Zhu, Y., Chen, Y. & Yang, L. The clinical landscape of CAR-engineered unconventional T cells. Trends Cancer 11, 520\u2013539 (2025).","journal-title":"Trends Cancer"},{"key":"1322_CR315","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1016\/j.stem.2025.07.009","volume":"32","author":"X Hu","year":"2025","unstructured":"Hu, X. et al. Hypoimmune CD19 CAR T cells evade allorejection in patients with cancer and autoimmune disease. Cell Stem Cell 32, 1356\u20131368.e4 (2025).","journal-title":"Cell Stem Cell"},{"key":"1322_CR316","doi-asserted-by":"publisher","first-page":"6317","DOI":"10.1016\/j.cell.2025.07.046","volume":"188","author":"Z Wu","year":"2025","unstructured":"Wu, Z. et al. Glycan shielding enables TCR-sufficient allogeneic CAR-T therapy. Cell 188, 6317\u20136334.e21 (2025).","journal-title":"Cell"},{"key":"1322_CR317","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.jtct.2025.09.044","volume":"32","author":"AY Cheema","year":"2026","unstructured":"Cheema, A. Y. et al. Under the hood: evidence-based review of allogeneic chimeric antigen receptor T cells for hematologic malignancies. Transplant. Cell. Ther. 32, 125\u2013140 (2026).","journal-title":"Transplant. Cell. Ther."},{"key":"1322_CR318","doi-asserted-by":"publisher","first-page":"eaaj2013","DOI":"10.1126\/scitranslmed.aaj2013","volume":"9","author":"W Qasim","year":"2017","unstructured":"Qasim, W. et al. Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells. Sci. Transl. Med. 9, eaaj2013 (2017).","journal-title":"Sci. Transl. Med."},{"key":"1322_CR319","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1200\/JCO-24-01933","volume":"43","author":"FL Locke","year":"2025","unstructured":"Locke, F. L. et al. Allogeneic chimeric antigen receptor T-cell products cemacabtagene ansegedleucel\/ALLO-501 in relapsed\/refractory large B-cell lymphoma: phase I experience from the ALPHA2\/ALPHA clinical studies. J. Clin. Oncol. 43, 1695\u20131705 (2025).","journal-title":"J. Clin. Oncol."},{"key":"1322_CR320","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1158\/2159-8290.CD-24-0102","volume":"14","author":"SK Pal","year":"2024","unstructured":"Pal, S. K. et al. CD70-targeted allogeneic CAR T-Cell therapy for advanced clear cell renal cell carcinoma. Cancer Discov. 14, 1176\u20131189 (2024).","journal-title":"Cancer Discov."},{"key":"1322_CR321","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1126\/science.abm0594","volume":"375","author":"JG Rurik","year":"2022","unstructured":"Rurik, J. G. et al. CAR T cells produced in vivo to treat cardiac injury. Science 375, 91\u201396 (2022). This proof-of-concept study demonstrates the generation of transient CAR T cells in vivo using mRNA-loaded lipid nanoparticles to treat cardiac fibrosis.","journal-title":"Science"},{"key":"1322_CR322","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1038\/nnano.2017.57","volume":"12","author":"TT Smith","year":"2017","unstructured":"Smith, T. T. et al. In situ programming of leukaemia-specific T cells using synthetic DNA nanocarriers. Nat. Nanotechnol. 12, 813\u2013820 (2017).","journal-title":"Nat. Nanotechnol."},{"key":"1322_CR323","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1182\/blood.2024024523","volume":"144","author":"CJ Nicolai","year":"2024","unstructured":"Nicolai, C. J. et al. In vivo CAR T-cell generation in nonhuman primates using lentiviral vectors displaying a multidomain fusion ligand. Blood 144, 977\u2013987 (2024).","journal-title":"Blood"},{"key":"1322_CR324","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.cell.2022.12.022","volume":"186","author":"WA Nyberg","year":"2023","unstructured":"Nyberg, W. A. et al. An evolved AAV variant enables efficient genetic engineering of murine T cells. Cell 186, 446\u2013460.e19 (2023).","journal-title":"Cell"},{"key":"1322_CR325","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00508-1","volume":"11","author":"W Nawaz","year":"2021","unstructured":"Nawaz, W. et al. AAV-mediated in vivo CAR gene therapy for targeting human T-cell leukemia. Blood Cancer J. 11, 119 (2021).","journal-title":"Blood Cancer J."},{"key":"1322_CR326","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1038\/s41587-022-01245-x","volume":"40","author":"P Agarwalla","year":"2022","unstructured":"Agarwalla, P. et al. Bioinstructive implantable scaffolds for rapid in vivo manufacture and release of CAR-T cells. Nat. Biotechnol. 40, 1250\u20131258 (2022).","journal-title":"Nat. Biotechnol."},{"key":"1322_CR327","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1038\/s41587-023-02085-z","volume":"42","author":"JR Hamilton","year":"2024","unstructured":"Hamilton, J. R. et al. In vivo human T cell engineering with enveloped delivery vehicles. Nat. Biotechnol. 42, 1684\u20131692 (2024).","journal-title":"Nat. Biotechnol."},{"key":"1322_CR328","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.scib.2023.11.055","volume":"69","author":"G Zhao","year":"2024","unstructured":"Zhao, G., Zhang, Y., Xu, C.-F. & Wang, J. In vivo production of CAR-T cells using virus-mimetic fusogenic nanovesicles. Sci. Bull. 69, 354\u2013366 (2024).","journal-title":"Sci. Bull."},{"key":"1322_CR329","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/s41573-025-01291-5","volume":"25","author":"A Bot","year":"2025","unstructured":"Bot, A. et al. In vivo chimeric antigen receptor (CAR)-T cell therapy. Nat. Rev. Drug. Discov. 25, 116\u2013137 (2025).","journal-title":"Nat. Rev. Drug. Discov."},{"key":"1322_CR330","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1038\/s41586-026-10235-x","volume":"652","author":"WA Nyberg","year":"2026","unstructured":"Nyberg, W. A. et al. In vivo site-specific engineering to reprogram T cells. Nature 652, 712\u2013721 (2026). This work presents the first in vivo site-specific gene-editing platform for T cells to integrate CARs into the TRAC locus directly within the body, enabling stable, lineage-specific CAR T cell generation without ex vivo manufacturing.","journal-title":"Nature"},{"key":"1322_CR331","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1126\/science.ads8473","volume":"388","author":"TL Hunter","year":"2025","unstructured":"Hunter, T. L. et al. In vivo CAR T cell generation to treat cancer and autoimmune disease. Science 388, 1311\u20131317 (2025). This study advances the field of in vivo cell engineering by showing that CAR T cells can be generated directly within the body to effectively treat both cancer and autoimmune disorders, eliminating the need for complex ex vivo manufacturing.","journal-title":"Science"},{"key":"1322_CR332","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-026-04365-y","author":"O Nadeem","year":"2026","unstructured":"Nadeem, O. et al. Ciltacabtagene autoleucel in high-risk smoldering multiple myeloma: the CAR-PRISM phase 2 trial. Nat. Med. https:\/\/doi.org\/10.1038\/s41591-026-04365-y (2026).","journal-title":"Nat. Med."},{"key":"1322_CR333","doi-asserted-by":"publisher","first-page":"819","DOI":"10.4049\/jimmunol.137.3.819","volume":"137","author":"A Weiss","year":"1986","unstructured":"Weiss, A., Manger, B. & Imboden, J. Synergy between the T3\/antigen receptor complex and Tp44 in the activation of human T cells. J. Immunol. 137, 819\u2013825 (1986).","journal-title":"J. Immunol."},{"key":"1322_CR334","doi-asserted-by":"publisher","first-page":"3282","DOI":"10.4049\/jimmunol.136.9.3282","volume":"136","author":"PJ Martin","year":"1986","unstructured":"Martin, P. J. et al. A 44\u2009kilodalton cell surface homodimer regulates interleukin 2 production by activated human T lymphocytes. J. Immunol. 136, 3282\u20133287 (1986).","journal-title":"J. Immunol."},{"key":"1322_CR335","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1038\/cr.2016.142","volume":"27","author":"X Liu","year":"2017","unstructured":"Liu, X. et al. CRISPR\u2013Cas9-mediated multiplex gene editing in CAR-T cells. Cell Res. 27, 154\u2013157 (2017).","journal-title":"Cell Res."},{"key":"1322_CR336","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1158\/1078-0432.CCR-16-1300","volume":"23","author":"J Ren","year":"2017","unstructured":"Ren, J. et al. Multiplex genome editing to generate universal CAR T cells resistant to PD1 inhibition. Clin. Cancer Res. 23, 2255\u20132266 (2017).","journal-title":"Clin. Cancer Res."},{"key":"1322_CR337","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/S0140-6736(61)90693-6","volume":"2","author":"JF Miller","year":"1961","unstructured":"Miller, J. F. Immunological function of the thymus. Lancet 2, 748\u2013749 (1961).","journal-title":"Lancet"},{"key":"1322_CR338","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/205143a0","volume":"205","author":"MD Cooper","year":"1965","unstructured":"Cooper, M. D., Peterson, R. D. & Good, R. A. Delineation of the thymic and bursal lymphoid systems in the chicken. Nature 205, 143\u2013146 (1965).","journal-title":"Nature"},{"key":"1322_CR339","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1084\/jem.123.1.75","volume":"123","author":"MD Cooper","year":"1966","unstructured":"Cooper, M. D., Raymond, D. A., Peterson, R. D., South, M. A. & Good, R. A. The functions of the thymus system and the bursa system in the chicken. J. Exp. Med. 123, 75\u2013102 (1966).","journal-title":"J. Exp. Med."},{"key":"1322_CR340","doi-asserted-by":"publisher","first-page":"248","DOI":"10.3181\/00379727-114-28643","volume":"114","author":"WP Rowe","year":"1963","unstructured":"Rowe, W. P., Black, P. H. & Levey, R. H. Protective effect of neonatal thymectomy on mouse LCM infection. Proc. Soc. Exp. Biol. Med. 114, 248\u2013251 (1963).","journal-title":"Proc. Soc. Exp. Biol. Med."},{"key":"1322_CR341","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1038\/195347a0","volume":"195","author":"DM Parrott","year":"1962","unstructured":"Parrott, D. M. & East, J. Role of the thymus in neonatal life. Nature 195, 347\u2013348 (1962).","journal-title":"Nature"},{"key":"1322_CR342","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1038\/2281308a0","volume":"228","author":"JC Cerottini","year":"1970","unstructured":"Cerottini, J. C., Nordin, A. A. & Brunner, K. T. Specific in vitro cytotoxicity of thymus-derived lymphocytes sensitized to alloantigens. Nature 228, 1308\u20131309 (1970).","journal-title":"Nature"},{"key":"1322_CR343","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1084\/jem.135.4.890","volume":"135","author":"P Golstein","year":"1972","unstructured":"Golstein, P., Wigzell, H., Blomgren, H. & Svedmyr, E. A. Cells mediating specific in vitro cytotoxicity. II. Probable autonomy of thymus-processed lymphocytes (T cells) for the killing of allogeneic target cells. J. Exp. Med. 135, 890\u2013906 (1972).","journal-title":"J. Exp. Med."},{"key":"1322_CR344","doi-asserted-by":"publisher","first-page":"516","DOI":"10.4049\/jimmunol.85.5.516","volume":"85","author":"A Govaerts","year":"1960","unstructured":"Govaerts, A. Cellular antibodies in kidney homotransplantation. J. Immunol. 85, 516\u2013522 (1960).","journal-title":"J. Immunol."},{"key":"1322_CR345","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1084\/jem.134.6.1385","volume":"134","author":"P Golstein","year":"1971","unstructured":"Golstein, P., Erik, M. D., Svedmyr, A. J. & Wigzell, H. Cells mediating specific in vitro cytotoxicity. I. Detection of receptor-bearing lymphocytes. J. Exp. Med. 134, 1385\u20131402 (1971).","journal-title":"J. Exp. Med."},{"key":"1322_CR346","first-page":"115","volume":"14","author":"BD Brondz","year":"1968","unstructured":"Brondz, B. D. Complex specificity of immune lymphocytes in allogeneic cell cultures. Folia Biol. 14, 115\u2013131 (1968).","journal-title":"Folia Biol."},{"key":"1322_CR347","first-page":"20","volume":"16","author":"BD Brondz","year":"1970","unstructured":"Brondz, B. D. & Golberg, N. E. Further in vitro evidence for polyvalent specificity of immune lymphocytes. Folia Biol. 16, 20\u201328 (1970).","journal-title":"Folia Biol."},{"key":"1322_CR348","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1038\/251547a0","volume":"251","author":"RM Zinkernagel","year":"1974","unstructured":"Zinkernagel, R. M. & Doherty, P. C. Immunological surveillance against altered self components by sensitised T lymphocytes in lymphocytic choriomeningitis. Nature 251, 547\u2013548 (1974).","journal-title":"Nature"},{"key":"1322_CR349","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1038\/248701a0","volume":"248","author":"RM Zinkernagel","year":"1974","unstructured":"Zinkernagel, R. M. & Doherty, P. C. Restriction of in vitro T cell-mediated cytotoxicity in lymphocytic choriomeningitis within a syngeneic or semiallogeneic system. Nature 248, 701\u2013702 (1974).","journal-title":"Nature"},{"key":"1322_CR350","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1084\/jem.158.2.303","volume":"158","author":"R Shimonkevitz","year":"1983","unstructured":"Shimonkevitz, R., Kappler, J., Marrack, P. & Grey, H. Antigen recognition by H-2-restricted T cells. I. Cell-free antigen processing. J. Exp. Med. 158, 303\u2013316 (1983).","journal-title":"J. Exp. Med."},{"key":"1322_CR351","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/0092-8674(86)90019-X","volume":"44","author":"AR Townsend","year":"1986","unstructured":"Townsend, A. R. et al. The epitopes of influenza nucleoprotein recognized by cytotoxic T lymphocytes can be defined with short synthetic peptides. Cell 44, 959\u2013968 (1986).","journal-title":"Cell"},{"key":"1322_CR352","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/0092-8674(85)90103-5","volume":"42","author":"AR Townsend","year":"1985","unstructured":"Townsend, A. R., Gotch, F. M. & Davey, J. Cytotoxic T cells recognize fragments of the influenza nucleoprotein. Cell 42, 457\u2013467 (1985).","journal-title":"Cell"},{"key":"1322_CR353","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1038\/300655a0","volume":"300","author":"AR Townsend","year":"1982","unstructured":"Townsend, A. R. & Skehel, J. J. Influenza A specific cytotoxic T-cell clones that do not recognize viral glycoproteins. Nature 300, 655\u2013657 (1982).","journal-title":"Nature"},{"key":"1322_CR354","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1002\/eji.1830101006","volume":"10","author":"EL Reinherz","year":"1980","unstructured":"Reinherz, E. L., Hussey, R. E. & Schlossman, S. F. A monoclonal antibody blocking human T cell function. Eur. J. Immunol. 10, 758\u2013762 (1980).","journal-title":"Eur. J. Immunol."},{"key":"1322_CR355","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/0092-8674(82)90278-1","volume":"30","author":"EL Reinherz","year":"1982","unstructured":"Reinherz, E. L. et al. Antigen recognition by human T lymphocytes is linked to surface expression of the T3 molecular complex. Cell 30, 735\u2013743 (1982).","journal-title":"Cell"},{"key":"1322_CR356","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/0092-8674(83)90530-5","volume":"34","author":"BW McIntyre","year":"1983","unstructured":"McIntyre, B. W. & Allison, J. P. The mouse T cell receptor: structural heterogeneity of molecules of normal T cells defined by xenoantiserum. Cell 34, 739\u2013746 (1983).","journal-title":"Cell"},{"key":"1322_CR357","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.4049\/jimmunol.129.5.2293","volume":"129","author":"JP Allison","year":"1982","unstructured":"Allison, J. P., McIntyre, B. W. & Bloch, D. Tumor-specific antigen of murine T-lymphoma defined with monoclonal antibody. J. Immunol. 129, 2293\u20132300 (1982).","journal-title":"J. Immunol."},{"key":"1322_CR358","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1084\/jem.157.2.705","volume":"157","author":"SC Meuer","year":"1983","unstructured":"Meuer, S. C. et al. Clonotypic structures involved in antigen-specific human T cell function. Relationship to the T3 molecular complex. J. Exp. Med. 157, 705\u2013719 (1983).","journal-title":"J. Exp. Med."},{"key":"1322_CR359","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1126\/science.6606228","volume":"222","author":"SC Meuer","year":"1983","unstructured":"Meuer, S. C. et al. Identification of the receptor for antigen and major histocompatibility complex on human inducer T lymphocytes. Science 222, 1239\u20131242 (1983).","journal-title":"Science"},{"key":"1322_CR360","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1038\/303808a0","volume":"303","author":"SC Meuer","year":"1983","unstructured":"Meuer, S. C. et al. Evidence for the T3-associated 90\u2009K heterodimer as the T-cell antigen receptor. Nature 303, 808\u2013810 (1983).","journal-title":"Nature"},{"key":"1322_CR361","doi-asserted-by":"publisher","first-page":"4104","DOI":"10.1073\/pnas.80.13.4104","volume":"80","author":"EL Reinherz","year":"1983","unstructured":"Reinherz, E. L. et al. Comparison of T3-associated 49- and 43-kilodalton cell surface molecules on individual human T-cell clones: evidence for peptide variability in T-cell receptor structures. Proc. Natl Acad. Sci. USA 80, 4104\u20134108 (1983).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1322_CR362","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/0092-8674(83)90529-9","volume":"34","author":"J Kappler","year":"1983","unstructured":"Kappler, J., Kubo, R., Haskins, K., White, J. & Marrack, P. The mouse T cell receptor: comparison of MHC-restricted receptors on two T cell hybridomas. Cell 34, 727\u2013737 (1983).","journal-title":"Cell"},{"key":"1322_CR363","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/0092-8674(83)90232-5","volume":"35","author":"J Kappler","year":"1983","unstructured":"Kappler, J. et al. The major histocompatibility complex-restricted antigen receptor on T cells in mouse and man: identification of constant and variable peptides. Cell 35, 295\u2013302 (1983).","journal-title":"Cell"},{"key":"1322_CR364","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/nbt.2459","volume":"31","author":"CC Kloss","year":"2013","unstructured":"Kloss, C. C., Condomines, M., Cartellieri, M., Bachmann, M. & Sadelain, M. Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells. Nat. Biotechnol. 31, 71\u201375 (2013).","journal-title":"Nat. Biotechnol."},{"key":"1322_CR365","doi-asserted-by":"publisher","DOI":"10.1038\/mtna.2013.32","volume":"2","author":"Z Grada","year":"2013","unstructured":"Grada, Z. et al. TanCAR: a novel bispecific chimeric antigen receptor for cancer immunotherapy. Mol. Ther. Nucleic Acids 2, e105 (2013).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"1322_CR366","doi-asserted-by":"publisher","first-page":"1958","DOI":"10.1016\/j.cell.2018.10.024","volume":"175","author":"E Shifrut","year":"2018","unstructured":"Shifrut, E. et al. Genome-wide CRISPR screens in primary human T cells reveal key regulators of immune function. Cell 175, 1958\u20131971.e15 (2018).","journal-title":"Cell"},{"key":"1322_CR367","doi-asserted-by":"publisher","unstructured":"Liu, Q. et al. In vivo genome-wide CRISPR screens in human T cells to enhance T cell therapy for solid tumors. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/2025.09.23.678127 (2025).","DOI":"10.1101\/2025.09.23.678127"},{"key":"1322_CR368","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1084\/jem.141.6.1376","volume":"141","author":"H Cantor","year":"1975","unstructured":"Cantor, H. & Boyse, E. A. Functional subclasses of T-lymphocytes bearing different Ly antigens. I. The generation of functionally distinct T-cell subclasses is a differentiative process independent of antigen. J. Exp. Med. 141, 1376\u20131389 (1975).","journal-title":"J. Exp. Med."},{"key":"1322_CR369","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1084\/jem.141.1.227","volume":"141","author":"H Shiku","year":"1975","unstructured":"Shiku, H. et al. Expression of T-cell differentiation antigens on effector cells in cell-mediated cytotoxicity in vitro. Evidence for functional heterogeneity related to the surface phenotype of T cells. J. Exp. Med. 141, 227\u2013241 (1975).","journal-title":"J. Exp. Med."},{"key":"1322_CR370","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1038\/253219a0","volume":"253","author":"P Kisielow","year":"1975","unstructured":"Kisielow, P. et al. Ly antigens as markers for functionally distinct subpopulations of thymus-derived lymphocytes of the mouse. Nature 253, 219\u2013220 (1975).","journal-title":"Nature"},{"key":"1322_CR371","doi-asserted-by":"publisher","first-page":"4061","DOI":"10.1073\/pnas.76.8.4061","volume":"76","author":"EL Reinherz","year":"1979","unstructured":"Reinherz, E. L., Kung, P. C., Goldstein, G. & Schlossman, S. F. Separation of functional subsets of human T cells by a monoclonal antibody. Proc. Natl Acad. Sci. USA 76, 4061\u20134065 (1979).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1322_CR372","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1038\/294168a0","volume":"294","author":"EL Reinherz","year":"1981","unstructured":"Reinherz, E. L. et al. Antibody directed at a surface structure inhibits cytolytic but not suppressor function of human T lymphocytes. Nature 294, 168\u2013170 (1981).","journal-title":"Nature"},{"key":"1322_CR373","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1038\/294460a0","volume":"294","author":"T H\u00fcnig","year":"1981","unstructured":"H\u00fcnig, T. & Bevan, M. J. Specificity of T-cell clones illustrates altered self hypothesis. Nature 294, 460\u2013462 (1981).","journal-title":"Nature"},{"key":"1322_CR374","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1084\/jem.155.1.111","volume":"155","author":"TR H\u00fcnig","year":"1982","unstructured":"H\u00fcnig, T. R. & Bevan, M. J. Antigen recognition by cloned cytotoxic T lymphocytes follows rules predicted by the altered-self hypothesis. J. Exp. Med. 155, 111\u2013125 (1982).","journal-title":"J. Exp. Med."},{"key":"1322_CR375","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1002\/eji.1830040802","volume":"4","author":"GM Shearer","year":"1974","unstructured":"Shearer, G. M. Cell-mediated cytotoxicity to trinitrophenyl-modified syngeneic lymphocytes. Eur. J. Immunol. 4, 527\u2013533 (1974).","journal-title":"Eur. J. Immunol."},{"key":"1322_CR376","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1084\/jem.142.6.1349","volume":"142","author":"MJ Bevan","year":"1975","unstructured":"Bevan, M. J. The major histocompatibility complex determines susceptibility to cytotoxic T cells directed against minor histocompatibility antigens. J. Exp. Med. 142, 1349\u20131364 (1975).","journal-title":"J. Exp. Med."},{"key":"1322_CR377","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1084\/jem.142.5.1108","volume":"142","author":"RD Gordon","year":"1975","unstructured":"Gordon, R. D., Simpson, E. & Samelson, L. E. In vitro cell-mediated immune responses to the male specific(H-Y) antigen in mice. J. Exp. Med. 142, 1108\u20131120 (1975).","journal-title":"J. Exp. Med."},{"key":"1322_CR378","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1084\/jem.153.5.1198","volume":"153","author":"JW Kappler","year":"1981","unstructured":"Kappler, J. W., Skidmore, B., White, J. & Marrack, P. Antigen-inducible, H-2-restricted, interleukin-2-producing T cell hybridomas. Lack of independent antigen and H-2 recognition. J. Exp. Med. 153, 1198\u20131214 (1981).","journal-title":"J. Exp. Med."},{"key":"1322_CR379","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/308145a0","volume":"308","author":"Y Yanagi","year":"1984","unstructured":"Yanagi, Y. et al. A human T cell-specific cDNA clone encodes a protein having extensive homology to immunoglobulin chains. Nature 308, 145\u2013149 (1984).","journal-title":"Nature"},{"key":"1322_CR380","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1038\/308149a0","volume":"308","author":"SM Hedrick","year":"1984","unstructured":"Hedrick, S. M., Cohen, D. I., Nielsen, E. A. & Davis, M. M. Isolation of cDNA clones encoding T cell-specific membrane-associated proteins. Nature 308, 149\u2013153 (1984).","journal-title":"Nature"},{"key":"1322_CR381","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/308153a0","volume":"308","author":"SM Hedrick","year":"1984","unstructured":"Hedrick, S. M., Nielsen, E. A., Kavaler, J., Cohen, D. I. & Davis, M. M. Sequence relationships between putative T-cell receptor polypeptides and immunoglobulins. Nature 308, 153\u2013158 (1984).","journal-title":"Nature"},{"key":"1322_CR382","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/0092-8674(85)90086-8","volume":"41","author":"MM Le Beau","year":"1985","unstructured":"Le Beau, M. M., Diaz, M. O., Rowley, J. D. & Mak, T. W. Chromosomal localization of the human T cell receptor \u03b2-chain genes. Cell 41, 335 (1985).","journal-title":"Cell"},{"key":"1322_CR383","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1016\/0092-8674(84)90444-6","volume":"37","author":"M Malissen","year":"1984","unstructured":"Malissen, M. et al. Mouse T cell antigen receptor: structure and organization of constant and joining gene segments encoding the \u03b2 polypeptide. Cell 37, 1101\u20131110 (1984).","journal-title":"Cell"},{"key":"1322_CR384","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/0092-8674(84)90369-6","volume":"37","author":"G Siu","year":"1984","unstructured":"Siu, G. et al. The human T cell antigen receptor is encoded by variable, diversity, and joining gene segments that rearrange to generate a complete V gene. Cell 37, 393\u2013401 (1984).","journal-title":"Cell"},{"key":"1322_CR385","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1038\/310506a0","volume":"310","author":"Y Yoshikai","year":"1984","unstructured":"Yoshikai, Y., Yanagi, Y., Suciu-Foca, N. & Mak, T. W. Presence of T-cell receptor mRNA in functionally distinct T cells and elevation during intrathymic differentiation. Nature 310, 506\u2013508 (1984).","journal-title":"Nature"},{"key":"1322_CR386","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1038\/316837a0","volume":"316","author":"Y Yoshikai","year":"1985","unstructured":"Yoshikai, Y. et al. Organization and sequences of the variable, joining and constant region genes of the human T-cell receptor \u03b1-chain. Nature 316, 837\u2013840 (1985).","journal-title":"Nature"},{"key":"1322_CR387","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1038\/312521a0","volume":"312","author":"Y Yoshikai","year":"1984","unstructured":"Yoshikai, Y. et al. Sequence and expression of transcripts of the human T-cell receptor \u03b2-chain genes. Nature 312, 521\u2013524 (1984).","journal-title":"Nature"},{"key":"1322_CR388","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/311387a0","volume":"311","author":"SP Clark","year":"1984","unstructured":"Clark, S. P. et al. Identification of a diversity segment of human T-cell receptor \u03b2-chain, and comparison with the analogous murine element. Nature 311, 387\u2013389 (1984).","journal-title":"Nature"},{"key":"1322_CR389","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1038\/311385a0","volume":"311","author":"B Toyonaga","year":"1984","unstructured":"Toyonaga, B., Yanagi, Y., Suciu-Foca, N., Minden, M. & Mak, T. W. Rearrangements of T-cell receptor gene YT35 in human DNA from thymic leukaemia T-cell lines and functional T-cell clones. Nature 311, 385\u2013387 (1984).","journal-title":"Nature"},{"key":"1322_CR390","doi-asserted-by":"publisher","first-page":"3851","DOI":"10.1073\/pnas.81.12.3851","volume":"81","author":"O Acuto","year":"1984","unstructured":"Acuto, O. et al. Purification and NH2-terminal amino acid sequencing of the \u03b2 subunit of a human T-cell antigen receptor. Proc. Natl Acad. Sci. USA 81, 3851\u20133855 (1984).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1322_CR391","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1038\/309757a0","volume":"309","author":"H Saito","year":"1984","unstructured":"Saito, H. et al. Complete primary structure of a heterodimeric T-cell receptor deduced from cDNA sequences. Nature 309, 757\u2013762 (1984).","journal-title":"Nature"},{"key":"1322_CR392","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1038\/327677a0","volume":"327","author":"YH Chien","year":"1987","unstructured":"Chien, Y. H., Iwashima, M., Kaplan, K. B., Elliott, J. F. & Davis, M. M. A new T-cell receptor gene located within the \u03b1 locus and expressed early in T-cell differentiation. Nature 327, 677\u2013682 (1987).","journal-title":"Nature"},{"key":"1322_CR393","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1038\/312036a0","volume":"312","author":"H Saito","year":"1984","unstructured":"Saito, H. et al. A third rearranged and expressed gene in a clone of cytotoxic T lymphocytes. Nature 312, 36\u201340 (1984).","journal-title":"Nature"},{"key":"1322_CR394","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1016\/0092-8674(89)90609-0","volume":"59","author":"JJ Lafaille","year":"1989","unstructured":"Lafaille, J. J., DeCloux, A., Bonneville, M., Takagaki, Y. & Tonegawa, S. Junctional sequences of T cell receptor \u03b3\u03b4 genes: implications for \u03b3\u03b4 T cell lineages and for a novel intermediate of V\u2013(D)\u2013J joining. Cell 59, 859\u2013870 (1989).","journal-title":"Cell"},{"key":"1322_CR395","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/0092-8674(85)90027-3","volume":"43","author":"LE Samelson","year":"1985","unstructured":"Samelson, L. E., Harford, J. B. & Klausner, R. D. Identification of the components of the murine T cell antigen receptor complex. Cell 43, 223\u2013231 (1985).","journal-title":"Cell"},{"key":"1322_CR396","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/0092-8674(85)90321-6","volume":"40","author":"MB Brenner","year":"1985","unstructured":"Brenner, M. B., Trowbridge, I. S. & Strominger, J. L. Cross-linking of human T cell receptor proteins: association between the T cell idiotype \u03b2 subunit and the T3 glycoprotein heavy subunit. Cell 40, 183\u2013190 (1985).","journal-title":"Cell"},{"key":"1322_CR397","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1038\/329512a0","volume":"329","author":"PJ Bjorkman","year":"1987","unstructured":"Bjorkman, P. J. et al. The foreign antigen binding site and T cell recognition regions of class I histocompatibility antigens. Nature 329, 512\u2013518 (1987).","journal-title":"Nature"},{"key":"1322_CR398","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1038\/329506a0","volume":"329","author":"PJ Bjorkman","year":"1987","unstructured":"Bjorkman, P. J. et al. Structure of the human class I histocompatibility antigen, HLA-A2. Nature 329, 506\u2013512 (1987).","journal-title":"Nature"},{"key":"1322_CR399","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1038\/384134a0","volume":"384","author":"DN Garboczi","year":"1996","unstructured":"Garboczi, D. N. et al. Structure of the complex between human T-cell receptor, viral peptide and HLA-A2. Nature 384, 134\u2013141 (1996).","journal-title":"Nature"},{"key":"1322_CR400","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1158\/2159-8290.CD-20-1243","volume":"11","author":"D Wang","year":"2021","unstructured":"Wang, D. et al. CRISPR screening of CAR T cells and cancer stem cells reveals critical dependencies for cell-based therapies. Cancer Discov. 11, 1192\u20131211 (2021).","journal-title":"Cancer Discov."},{"key":"1322_CR401","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1126\/science.271.5256.1734","volume":"271","author":"DR Leach","year":"1996","unstructured":"Leach, D. R., Krummel, M. F. & Allison, J. P. Enhancement of antitumor immunity by CTLA-4 blockade. Science 271, 1734\u20131736 (1996).","journal-title":"Science"},{"key":"1322_CR402","doi-asserted-by":"publisher","first-page":"eabq3010","DOI":"10.1126\/scitranslmed.abq3010","volume":"14","author":"G Ottaviano","year":"2022","unstructured":"Ottaviano, G. et al. Phase 1 clinical trial of CRISPR-engineered CAR19 universal T cells for treatment of children with refractory B cell leukemia. Sci. Transl. Med. 14, eabq3010 (2022).","journal-title":"Sci. Transl. Med."},{"key":"1322_CR403","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1056\/NEJM198512053132327","volume":"313","author":"SA Rosenberg","year":"1985","unstructured":"Rosenberg, S. A. et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N. Engl. J. Med. 313, 1485\u20131492 (1985).","journal-title":"N. Engl. J. Med."},{"key":"1322_CR404","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1126\/science.3489291","volume":"233","author":"SA Rosenberg","year":"1986","unstructured":"Rosenberg, S. A., Spiess, P. & Lafreniere, R. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 233, 1318\u20131321 (1986).","journal-title":"Science"},{"key":"1322_CR405","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","volume":"382","author":"M Wang","year":"2020","unstructured":"Wang, M. et al. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. N. Engl. J. Med. 382, 1331\u20131342 (2020).","journal-title":"N. Engl. J. Med."},{"key":"1322_CR406","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa2024850","volume":"384","author":"NC Munshi","year":"2021","unstructured":"Munshi, N. C. et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N. Engl. J. Med. 384, 705\u2013716 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1322_CR407","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","volume":"396","author":"JS Abramson","year":"2020","unstructured":"Abramson, J. S. et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet 396, 839\u2013852 (2020).","journal-title":"Lancet"},{"key":"1322_CR408","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu, S. S. et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N. Engl. J. Med. 377, 2531\u20132544 (2017).","journal-title":"N. Engl. J. Med."},{"key":"1322_CR409","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","volume":"398","author":"JG Berdeja","year":"2021","unstructured":"Berdeja, J. G. et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study. Lancet 398, 314\u2013324 (2021).","journal-title":"Lancet"},{"key":"1322_CR410","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2406526","volume":"391","author":"C Roddie","year":"2024","unstructured":"Roddie, C. et al. Obecabtagene autoleucel in adults with B-cell acute lymphoblastic leukemia. N. Engl. J. Med. 391, 2219\u20132230 (2024).","journal-title":"N. Engl. J. Med."},{"key":"1322_CR411","first-page":"2311","volume":"13","author":"A Bernard","year":"1984","unstructured":"Bernard, A. & Boumsell, L. Human leukocyte differentiation antigens [French]. Presse Medicale 13, 2311\u20132316 (1984).","journal-title":"Presse Medicale"},{"key":"1322_CR412","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1038\/42523","volume":"387","author":"GF Gao","year":"1997","unstructured":"Gao, G. F. et al. Crystal structure of the complex between human CD8\u03b1(\u03b1) and HLA-A2. Nature 387, 630\u2013634 (1997).","journal-title":"Nature"},{"key":"1322_CR413","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/S1074-7613(00)80635-4","volume":"9","author":"PS Kern","year":"1998","unstructured":"Kern, P. S. et al. Structural basis of CD8 coreceptor function revealed by crystallographic analysis of a murine CD8\u03b1\u03b1 ectodomain fragment in complex with H-2Kb. Immunity 9, 519\u2013530 (1998).","journal-title":"Immunity"},{"key":"1322_CR414","doi-asserted-by":"publisher","first-page":"2554","DOI":"10.4049\/jimmunol.0901276","volume":"183","author":"R Wang","year":"2009","unstructured":"Wang, R., Natarajan, K. & Margulies, D. H. Structural basis of the CD8\u03b1\u03b2\/MHC class I interaction: focused recognition orients CD8\u03b2 to a T cell proximal position. J. Immunol. 183, 2554\u20132564 (2009).","journal-title":"J. Immunol."},{"key":"1322_CR415","doi-asserted-by":"publisher","first-page":"10799","DOI":"10.1073\/pnas.191124098","volume":"98","author":"JH Wang","year":"2001","unstructured":"Wang, J. H. et al. Crystal structure of the human CD4 N-terminal two-domain fragment complexed to a class II MHC molecule. Proc. Natl Acad. Sci. USA 98, 10799\u201310804 (2001).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1322_CR416","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/j.immuni.2005.11.002","volume":"23","author":"H-C Chang","year":"2005","unstructured":"Chang, H.-C. et al. Structural and mutational analyses of a CD8\u03b1\u03b2 heterodimer and comparison with the CD8\u03b1\u03b1 homodimer. Immunity 23, 661\u2013671 (2005).","journal-title":"Immunity"},{"key":"1322_CR417","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/336079a0","volume":"336","author":"AM Norment","year":"1988","unstructured":"Norment, A. M., Salter, R. D., Parham, P., Engelhard, V. H. & Littman, D. R. Cell\u2013cell adhesion mediated by CD8 and MHC class I molecules. Nature 336, 79\u201381 (1988).","journal-title":"Nature"},{"key":"1322_CR418","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1084\/jem.169.1.149","volume":"169","author":"Y Rosenstein","year":"1989","unstructured":"Rosenstein, Y., Ratnofsky, S., Burakoff, S. J. & Herrmann, S. H. Direct evidence for binding of CD8 to HLA class I antigens. J. Exp. Med. 169, 149\u2013160 (1989).","journal-title":"J. Exp. Med."},{"key":"1322_CR419","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/0167-5699(83)90094-4","volume":"4","author":"EL Reinherz","year":"1983","unstructured":"Reinherz, E. L., Meuer, S. C. & Schlossman, S. F. The delineation of antigen receptors on human T lymphocytes. Immunol. Today 4, 5\u20138 (1983).","journal-title":"Immunol. Today"},{"key":"1322_CR420","doi-asserted-by":"publisher","first-page":"5031","DOI":"10.1073\/pnas.87.13.5031","volume":"87","author":"PS Linsley","year":"1990","unstructured":"Linsley, P. S., Clark, E. A. & Ledbetter, J. A. T-cell antigen CD28 mediates adhesion with B cells by interacting with activation antigen B7\/BB-1. Proc. Natl Acad. Sci. USA 87, 5031\u20135035 (1990).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1322_CR421","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1089\/scd.1.1998.7.437","volume":"7","author":"BL Levine","year":"1998","unstructured":"Levine, B. L. et al. Large-scale production of CD4+ T cells from HIV-1-infected donors after CD3\/CD28 costimulation. J. Hematother. 7, 437\u2013448 (1998).","journal-title":"J. Hematother."},{"key":"1322_CR422","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1038\/328267a0","volume":"328","author":"JF Brunet","year":"1987","unstructured":"Brunet, J. F. et al. A new member of the immunoglobulin superfamily\u2014CTLA-4. Nature 328, 267\u2013270 (1987).","journal-title":"Nature"},{"key":"1322_CR423","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1016\/j.cell.2023.03.006","volume":"186","author":"P Sharma","year":"2023","unstructured":"Sharma, P. et al. Immune checkpoint therapy\u2014current perspectives and future directions. Cell 186, 1652\u20131669 (2023).","journal-title":"Cell"},{"key":"1322_CR424","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-025-02856-w","author":"L Goudy","year":"2025","unstructured":"Goudy, L. et al. Integrated epigenetic and genetic programming of primary human T cells. Nat. Biotechnol. https:\/\/doi.org\/10.1038\/s41587-025-02856-w (2025).","journal-title":"Nat. Biotechnol."},{"key":"1322_CR425","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1038\/s41586-025-09489-8","volume":"646","author":"NH Knudsen","year":"2025","unstructured":"Knudsen, N. H. et al. In vivo CRISPR screens identify modifiers of CAR T cell function in myeloma. Nature 646, 953\u2013962 (2025).","journal-title":"Nature"},{"key":"1322_CR426","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1038\/s41586-025-09507-9","volume":"646","author":"P Datlinger","year":"2025","unstructured":"Datlinger, P. et al. Systematic discovery of CRISPR-boosted CAR T cell immunotherapies. Nature 646, 963\u2013972 (2025).","journal-title":"Nature"},{"key":"1322_CR427","doi-asserted-by":"publisher","first-page":"eabj4008","DOI":"10.1126\/science.abj4008","volume":"375","author":"R Schmidt","year":"2022","unstructured":"Schmidt, R. et al. CRISPR activation and interference screens decode stimulation responses in primary human T cells. Science 375, eabj4008 (2022).","journal-title":"Science"},{"key":"1322_CR428","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1038\/s41587-025-02845-z","volume":"44","author":"H Liu","year":"2026","unstructured":"Liu, H. et al. A tumor-on-a-chip for in vitro study of CAR-T cell immunotherapy in solid tumors. Nat. Biotechnol.\u00a044, 959\u2013975 (2026).","journal-title":"Nat. Biotechnol."},{"key":"1322_CR429","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1038\/s41586-023-06415-8","volume":"620","author":"JL Watson","year":"2023","unstructured":"Watson, J. L. et al. De novo design of protein structure and function with RFdiffusion. Nature 620, 1089\u20131100 (2023).","journal-title":"Nature"},{"key":"1322_CR430","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1126\/science.abq0225","volume":"378","author":"KG Daniels","year":"2022","unstructured":"Daniels, K. G. et al. Decoding CAR T cell phenotype using combinatorial signaling motif libraries and machine learning. Science 378, 1194\u20131200 (2022).","journal-title":"Science"},{"key":"1322_CR431","doi-asserted-by":"publisher","first-page":"2298","DOI":"10.1016\/j.ccell.2025.09.007","volume":"43","author":"F Di Meo","year":"2025","unstructured":"Di Meo, F. et al. Developing SEMA4A-directed CAR T cells to overcome low BCMA antigen density in multiple myeloma. Cancer Cell 43, 2298\u20132310.e6 (2025).","journal-title":"Cancer Cell"},{"key":"1322_CR432","doi-asserted-by":"publisher","DOI":"10.1038\/s41551-025-01527-0","author":"\u00c1 Ram\u00edrez-Fern\u00e1ndez","year":"2025","unstructured":"Ram\u00edrez-Fern\u00e1ndez, \u00c1 et al. CCR5-targeted allogeneic \u03b3\u2013\u03b4 CD19 chimeric antigen receptor T cells for HIV-associated B cell-malignancy immunotherapy. Nat. Biomed. Eng. https:\/\/doi.org\/10.1038\/s41551-025-01527-0 (2025).","journal-title":"Nat. Biomed. Eng."},{"key":"1322_CR433","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1038\/s41586-025-09087-8","volume":"643","author":"H Rafei","year":"2025","unstructured":"Rafei, H. et al. CREM is a regulatory checkpoint of CAR and IL-15 signalling in NK cells. Nature 643, 1076\u20131086 (2025).","journal-title":"Nature"},{"key":"1322_CR434","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1038\/s41586-025-09393-1","volume":"645","author":"Y Zhao","year":"2025","unstructured":"Zhao, Y. et al. Expanding the cytokine receptor alphabet reprograms T cells into diverse states. Nature 645, 1039\u20131050 (2025).","journal-title":"Nature"},{"key":"1322_CR435","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1016\/j.ccell.2025.05.006","volume":"43","author":"A Benton","year":"2025","unstructured":"Benton, A. et al. Mutant KRAS peptide targeted CAR-T cells engineered for cancer therapy. Cancer Cell 43, 1365\u20131376.e5 (2025).","journal-title":"Cancer Cell"},{"key":"1322_CR436","doi-asserted-by":"publisher","first-page":"eadn3816","DOI":"10.1126\/sciadv.adn3816","volume":"10","author":"J Fr\u00f6se","year":"2024","unstructured":"Fr\u00f6se, J. et al. Development of an antigen-based approach to noninvasively image CAR T cells in real time and as a predictive tool. Sci. Adv. 10, eadn3816 (2024).","journal-title":"Sci. Adv."},{"key":"1322_CR437","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.1038\/s41551-025-01415-7","volume":"9","author":"V Morath","year":"2025","unstructured":"Morath, V. et al. PET-based tracking of CAR T cells and viral gene transfer using a cell surface reporter that binds to lanthanide complexes. Nat. Biomed. Eng. 9, 1886\u20131906 (2025).","journal-title":"Nat. Biomed. Eng."},{"key":"1322_CR438","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.ccell.2025.09.011","volume":"44","author":"S Herbrich","year":"2026","unstructured":"Herbrich, S. et al. TET2-mutant clonal hematopoiesis enhances macrophage antigen presentation and improves immune checkpoint therapy in solid tumors. Cancer Cell 44, 187\u2013202.e7 (2026).","journal-title":"Cancer Cell"},{"key":"1322_CR439","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1016\/j.cell.2026.02.004","volume":"189","author":"S Liu","year":"2026","unstructured":"Liu, S. et al. \u03b2-Hydroxybutyrate enhances the metabolic fitness of CAR T cells in cancer. Cell 189, 1701\u20131716.e24 (2026).","journal-title":"Cell"},{"key":"1322_CR440","doi-asserted-by":"publisher","first-page":"28950","DOI":"10.1073\/pnas.2012495117","volume":"117","author":"S Kobayashi","year":"2020","unstructured":"Kobayashi, S. et al. A biomimetic five-module chimeric antigen receptor (5MCAR) designed to target and eliminate antigen-specific T cells. Proc. Natl Acad. Sci. USA 117, 28950\u201328959 (2020).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1322_CR441","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/s41586-020-2403-9","volume":"583","author":"C Amor","year":"2020","unstructured":"Amor, C. et al. Senolytic CAR T cells reverse senescence-associated pathologies. Nature 583, 127\u2013132 (2020).","journal-title":"Nature"},{"key":"1322_CR442","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1038\/s41586-019-1546-z","volume":"573","author":"H Aghajanian","year":"2019","unstructured":"Aghajanian, H. et al. Targeting cardiac fibrosis with engineered T cells. Nature 573, 430\u2013433 (2019).","journal-title":"Nature"},{"key":"1322_CR443","doi-asserted-by":"publisher","first-page":"2898","DOI":"10.1016\/j.cell.2026.03.002","volume":"189","author":"Z Zhang","year":"2026","unstructured":"Zhang, Z. et al. A convergent uPAR-positive tumor ecosystem creates broad vulnerability to CAR T cell therapy. Cell 189,\u00a02898\u20132917.e42\u00a0(2026).","journal-title":"Cell"}],"container-title":["Nature Reviews Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41577-026-01322-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41577-026-01322-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41577-026-01322-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T16:55:47Z","timestamp":1783011347000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41577-026-01322-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,2]]},"references-count":443,"alternative-id":["1322"],"URL":"https:\/\/doi.org\/10.1038\/s41577-026-01322-1","relation":{},"ISSN":["1474-1733","1474-1741"],"issn-type":[{"value":"1474-1733","type":"print"},{"value":"1474-1741","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,2]]},"assertion":[{"value":"1 June 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"P.S. discloses that she is a consultant and member of the scientific advisory board for each of Achelois, Adaptive Biotechnologies, Akoya Biosciences, Apricity, Asher Bio, BioAtla LLC, BioNTech, Candel Therapeutics, Catalio, C-Reveal Therapeutics, Dragonfly Therapeutics, Earli Inc, Enable Medicine, Glympse, Gyges, Henlius\/Hengenix, Hummingbird, ImaginAb, InterVenn Biosciences, JSL Health, LAVA Therapeutics, Lytix Biopharma, Matrisome, Neuvogen, NTx, Oncolytics, Osteologic, PBM Capital, Phenomic AI, Polaris Pharma, Pyrojas, Inc., Soley Therapeutics, Sporos, Spotlight, Time Bioventures, Trained Therapeutix Discovery, Two Bear Capital, Vironexis and Xilis, Inc.; and is an inventor on patents\/patent applications (61\/247,438; 16\/661,867; 17\/252,002). H.R. is an inventor on patents\/patent applications (18\/865,045; 17\/757,503). R.U. declares no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}